Audiological practices employed by audiologists in the management of adult patients with multi-drug resistant tuberculosis in South Africa. by Govender, Melesha.
AUDIOLOGICAL PRACTICES EMPLOYED BY AUDIOLOGISTS IN THE 
MANAGEMENT OF ADULT PATIENTS WITH MULTI-DRUG RESISTANT 









SUBMITTED IN FULFILMENT OF THE 
REQUIREMENTS FOR THE DEGREE OF 
 
 
MASTER OF COMMUNICATION PATHOLOGY  
(AUDIOLOGY)  
 
IN THE DISCIPLINE OF AUDIOLOGY 
SCHOOL OF HEALTH SCIENCES 
UNIVERSITY OF KWA ZULU-NATAL 
WESTVILLE CAMPUS 
 













The pages of this dissertation reflect the immense dedication and academic grandeur, not only 
of myself, but of those individuals with whom I have formed lasting relationships. Though 
the process of this postgraduate work has been one of hard work and challenges, it would not 
have been possible without the contribution of the following people whom I wish to offer my 
sincerest thanks and appreciation: 
 
To God, for being an ever guiding light to what seemed to be an endless tunnel. 
To my mother (Poovendri), father (Dan), sister (Yerusha) and brother (Preven), there are no 
words for how grateful I am for all the inspiration and motivation to complete this 
dissertation. 
To my research supervisor, Ms. J. Paken. I am truly grateful for your dedication to this study, 
as well as, the knowledge and guidance you have given me. 
To my grandparents for their on-going support and love. 
To my statistician, Ms. T. Reddy, for your patience and assistance with the statistical analysis 
of this research study. 
To my translator, Mr. K. Pillay and back translator Ms. J. Marais. 
To the participants of the study, for voluntary participation and knowledge shared. 
To my friends and the staff of Eshowe District Hospital. 






Aminoglycosides, such as amikacin and kanamycin, are part of the treatment for Multi-Drug 
Resistant Tuberculosis; however, it is ototoxic and the need for audiological monitoring is, 
therefore, emphasised. However, there are currently no explicit guidelines for monitoring 
ototoxicity in the South African context. Consequently, there is no standardised method for 
monitoring ototoxicity; however, audiologists are providing the service. Often adaptations to 
international protocols make them contextually relevant. Therefore, this study aims to 
describe the audiological practices employed by audiologists in the management of adult 
patients with MDR-TB in South Africa. A descriptive survey design was used. A 
questionnaire was developed and included the following aspects such as: identification and 
criteria used for patients with MDR-TB, baseline practices, monitoring procedures and post 
treatment management. Ninety-three audiologists contributed data for this study. Descriptive 
statistics and inferential statistics were used in the analysis of data. Results revealed that 80% 
of audiologists are aware of international guidelines, 93% reportedly provide pre-treatment 
counselling; while, 87% of audiologists conduct baseline assessments prior to the 
administration of MDR-TB treatment. Furthermore, 19% of audiologists conduct HFA and 
indicated that there is a lack of high frequency audiometers due is to financial constraints. 
The following were cited as reasons for the modification to the international guidelines:  lack 
of specialised equipment, time constraints and large caseloads, as well as, understaffed 
departments. In addition, 74% of the audiologists are able to conduct periodic assessments 
monthly, while 72% of audiologists conduct a full audiological assessment after the cessation 
of MDR-TB treatment and 96% of audiologists conduct post treatment counselling. The 
findings of this study may, thus, inform policy by allowing for evidence-based ototoxicity 
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1.1. Introduction  
This chapter addresses the aspects related to the research problem and the rationale of 
the study. In addition, it also provides clarity on specific terminologies used in the study. 
Furthermore, an outline of the chapters is presented.  
 
1.2. Study Problem 
According to World Health Organisation (WHO) (2012), Tuberculosis (TB) is one of 
the leading infectious diseases in the world. More specifically, South Africa is one of the five 
countries that have the largest number of incident cases (410 00 – 520 000), mainly due to the 
emergence of multi-drug resistant tuberculosis (MDR-TB), which has left a strain within the 
health care system (WHO, 2014). 
 
MDR-TB is defined as a resistance to isoniazid and rifampicin, which requires long-
term treatment of injectable aminoglycosides (WHO, 2008), as these aminoglycosides have 
resilience against gram-negative infections (WHO, 2008).  However, it is well known that 
aminoglycosides are ototoxic in nature (Jones, 2008). Therefore, audiologists need to be 
alerted or informed of patients who are undergoing ototoxic treatment, as they may be at risk 
of developing an aminoglycoside-induced hearing loss. Thus, with the high prevalence of 
MDR-TB in South Africa many audiologists would have to conduct ototoxicity monitoring, 
as these patients are susceptible to hearing impairment and would benefit from identifying 
hearing loss early. The sense of hearing is regarded to be one of the most important of all 
senses, as hearing has the ability to provide empowerment and enrichment to a patient’s life 
(Oticon, 2000). This allows the patients to socialise, work and communicate in a relaxed 
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manner (Oticon, 2000). It also has the ability to keep one safe by alerting us of potential 
dangers that may occur (Oticon, 2000). A hearing loss may lead to an individual feeling 
isolated from everyday activities (Valente, Hosford-Dunn, & Roeser, 2011). Thus, the 
audiologist plays a key role in helping patients habituate to the auditory changes they 
experience. Therefore, audiologists are vital in the management of a patient undergoing 
multi-drug resistant TB treatment. 
 
1.3. Rationale for the Study 
Developing countries, such as South Africa, have financial constraints on their 
healthcare system due to the competing budgetary demands from life-threatening and/or 
communicable diseases (Harris et al., 2012). In addition to these constraints, there are 
minimal audiological services available. However, the occurrence of hearing loss, due to 
MDR-TB, is on the rise (WHO, 2008).   
 
Although there are international guidelines available, there are no explicit 
contextually relevant guidelines for South African audiologists to utilise and it is important 
for audiologists to know that they are ethically obligated to follow evidence based best 
practice guidelines. It is the responsibility of the audiologist to provide a service that is within 
their scope of practice or make other arrangements to make access to the service possible 
(Department of Health [DOH], 2001). Furthermore, the need to develop and validate 
ototoxicity screening and monitoring tools for developing world countries should not be left 
ignored, but rather acknowledged (Harris et al., 2012).  
 
There is also a need for further investigation on the management of hearing loss in a 
patient with MDR-TB, as there are no specific guidelines for managing ototoxicity. Based on 
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anecdotal experience, there is currently no method being utilised to protect the deterioration 
of a patient’s hearing status against the effects of ototoxic medication in South Africa. Thus, 
the need for appropriate detection and management of ototoxicity is reliant on effective 
audiological monitoring. However, there are many unanswered questions about the tests and 
protocols used, and there is wide variation in results (National Health and Medical Research 
Council, 2002), as there are no specific protocols or guidelines for South African audiologists 
to utilise. However, there are audiologists who are practicing in a way that allows for 
maximising of resources in an effective manner to ensure a high quality of healthcare. 
Critical consideration needs to be taken when making adaptations to international protocols 
as these may not necessarily lead to the protocols being contextually relevant. Therefore, this 
study aims to describe these practices so that the information can be used to devise evidence-
based ototoxicity monitoring protocols for patients with MDR-TB. Furthermore, the findings 
of this study may help motivate for a more in-depth Department of Health (DOH) and Health 
Professions Council of South Africa (HPCSA) ototoxicity monitoring policy, allowing for 
uniformity among audiologists in TB clinics in South Africa.  
 
1.4. Terminology 
Aminoglycosides: “Groups of antibiotics that are used to treat many gram-negative bacterial, 
staphylococcal, and mycobacterial infections” (Neely, 2008, p. 250). 
High Frequency Audiometry: Encompasses air conduction threshold testing for the 
frequencies above 8000 Hz, ranging up to 16 or 20 kHz (American Academy of Audiology 
[AAA], 2009). 
Multi-drug resistant tuberculosis: A resistance to isoniazid and rifampicin, which requires 
long-term treatment of injectable aminoglycosides (WHO, 2008).  
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Ototoxicity: A hearing loss or vestibular dysfunction that occurs from the use of ototoxic 
therapeutic drugs (Kramer, 2008).  
Tuberculosis: An infectious disease of humans and animals caused by the tubercle bacillus 
and characterized by the formation of tubercles on the lungs and other tissues of the body, 
often developing long after the initial infection (American Heritage, 2008).  
 
1.5. Outline of Chapters 
Chapter 1 – Introduction 
This chapter highlights the study problem, rationale for the study and provides a brief 
description of each subsequent chapter. Additionally, common terminologies used throughout 
the research study are defined. 
 
Chapter 2 - Tuberculosis and Ototoxicity Monitoring Protocols 
This chapter reviews the aspects related to the role of the audiologist in ototoxicity 
monitoring, with reference to the patient with MDR-TB. In addition, it focuses on the 
theoretical aspects of TB and MDR-TB and the guidelines for the management of the patient 
with MDR-TB which have been provided to South African audiologists to utilise. 
Furthermore, it provides insight and/or a comparison to the international guidelines available. 
 
Chapter 3 – Methodology 
This chapter provides information related to the aims and objectives of the study, the study 
design, sample size, sampling method, as well as, the ethical and legal considerations of the 





Chapter 4 – Results 
This chapter presents the results of the study, which have been analysed using a quantitative 
method of analysis. The results are presented according to the objectives of the study.  
 
Chapter 5 – Discussion 
This chapter provides an explanation of the results obtained in the study with reference to 
relevant literature. In addition, it focuses on the audiological monitoring protocols currently 
employed by audiologists, as well as, the modifications made to international guidelines. 
 
Chapter 6 – Conclusion, Limitations and Recommendations 
This chapter provides a summary of the main findings of the study, limitations of the research 
study, as well as, the recommendations for future research. 
 
1.6. Summary 
This chapter provides a review of the study. According to the literature available, 
ototoxicity monitoring is regarded as an essential aspect related to the management of a 
patient with MDR-TB. South Africa has a high incidence rate of MDR-TB; thus, there is a 
great need for ototoxicity monitoring. However, there are currently no specific guidelines for 
South African audiologists to utilise which may hinder the process or has not made it possible 
to follow through with monitoring; although there are audiologists conducting ototoxicity 
monitoring in a ways that allows it to be contextually relevant. Therefore, this study attempts 
to describe the audiological practices employed by audiologists in the management of an 
adult patient with MDR-TB. The findings of this study may allow for evidence-based 




TUBERCULOSIS AND OTOTOXICITY MONITORING PROTOCOLS 
 
2.1. Introduction 
The ensuing chapter provides an overview of the scope of practice of the audiologist, 
as well as the role of the audiologist in ototoxicity monitoring, with reference to the patient 
with MDR-TB. In addition, the theoretical aspects of TB and MDR-TB will be discussed. 
Finally, the guidelines for the management of the patient with MDR-TB which have been 
provided to South African audiologists, will be critically examined.   
 
2.2. Audiologist Scope of Practice 
 Audiology is a paramedical profession involved in all aspects of auditory impairment 
and their associated communication disorders (South African Association of Audiologists 
[SAAA], 2002). Audiologists are responsible for the identification, assessment, diagnosis and 
management of individuals with peripheral or central auditory impairments, balance system 
disorders, tinnitus and associated neural system disorders (SAAA, 2002). These professionals 
are trained to evaluate the range, nature and degree of hearing loss in adults and children, as 
well as plan, implement and participate in the management of the individual with hearing 
impairment. Management of a hearing impairment includes a referral for medical 
management or selection and fitting of suitable amplification or assistive listening devices, or 
a combination of these (SAAA, 2002). 
 
According to Health Professions Council of South Africa (HPCSA) (2012) regulation, 
an audiological assessment should comprise of the following aspects i.e. case history, 
otoscopic examination, immittance (tympanometry and acoustic reflex thresholds), pure-tone 
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audiometry (air and bone conduction testing), speech audiometry (speech reception and 
speech discrimination testing), as well as special tests such as otoacoustic emissions (OAE), 
auditory brainstem response (ABR), and auditory steady state response (ASSR), when 
necessary. Audiologists also participate in the development and implementation of hearing 
conservation programs, through auditory training, counselling and fitting of protective 
devices such as ear plugs (SAAA, 2002). Furthermore, these health professionals are able to 
measure noise levels, recommend environmental modifications in order to reduce noise 
levels, as well as, partake in the management of the selection, purchase, installation, and 
evaluation of large-area amplification systems, when necessary (HPCSA, 2012).  
 
In addition, audiologists are also involved in rehabilitation which consists of 
evaluating, selecting, verifying, fitting and dispensing of amplification and assistive listening 
devices (HPCSA, 2012). Also, within the scope of practice for an audiologist is the 
assessment of a patient with hearing loss for cochlear implants and, counselling of the patient 
and family/caregivers in the use of and adjustment to the assistive listening device and the 
related psycho-social aspects of hearing loss, or other auditory dysfunctions, as well as, 
processes to enhance communication competence (HPCSA, 2012). The audiologist is also 
involved in the consultation and provision of vestibular and balance rehabilitation therapy to 
persons with vestibular and balance impairments; assessment and non-medical management 
of tinnitus, as well as provide training for professionals of related and/or allied services when 
needed (HPCSA, 2012).  
 
Although the HPCSA has provided South African audiologists with an in-depth scope 
of practice, little mention is made of the audiologist’s role and responsibility in ototoxicity 
monitoring. However, the role of the audiologist in this aspect is of great value for both the 
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patient who is undergoing the ototoxic drug therapy as well as the consulting physician. 
South Africa’s burden of disease is significantly higher compared to that of a developed 
country, which in turn suggests that there are a substantial number of individuals with poor 
health who may require treatment (Bradshaw et al., 2003). Treatment may be ototoxic or may 
have associated side effects that require monitoring; thus, audiologists need to be cognisant of 
their role in ototoxicity monitoring.  
 
2.2.1. Role of the Audiologist in Ototoxicity Monitoring 
One of the many responsibilities of an audiologist includes the planning and 
implementation of an auditory monitoring program for ototoxicity (Konrad-Martin, 
Wilmington, Gordon, Reavis, & Fausti, 2005). However, the continuation of the program 
requires a collaborative effort between the audiologist and the physicians involved; thus, a 
trans-disciplinary approach is needed (American Speech-Language-Hearing Association 
[ASHA], 1994). A trans-disciplinary approach may not only refer to the collaborative effort 
between all members of a rehabilitation team; it could also refer to the contribution of 
knowledge and skills, as well as, learning of all aspects that are required to provide the best 
possible services to a patient (Catlett & Halper, 1992). The process of identifying patients 
who are potentially at risk for ototoxicity should be initiated by the audiologist in 
consultation with the physicians (ASHA, 1994). The interaction between the audiologist and 
physician is valuable in respect to the changes that need to be made if ototoxicity is present 
(ASHA, 1994).  
 
Audiological monitoring for ototoxicity is usually conducted for two purposes i.e. 1) 
to detect ototoxic changes that may affect the speech frequencies, which in turn affect 
communication and it also allows the physician to make changes to the medication that is 
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being used, and 2) to monitor the ototoxic changes in the patient when the treatment regimen 
cannot be changed or once treatment is completed (Campbell, 2004). Changes in the 
treatment regimen include a reduction in the dosage, the scheduled timing of the dosage, 
temporary discontinuation or a switch to a less ototoxic drug (Mattucci & Vasquez, 2003). If 
the physician has decided to change the treatment of the patient, it is imperative that the 
audiologist establishes a new baseline in order to properly monitor ototoxicity (Mattucci & 
Vasquez, 2003). Thus, the need for a policy or guidelines for monitoring ototoxicity is 
emphasised, as this will allow the audiologist to follow a specific monitoring protocol for 
purposes of standardisation and consistency. This will encourage all audiologists to use a 
standardised method of testing, making it easier to document the progression of ototoxicity; 
thus, allowing for a more efficient referral system to specialised services and to gain the 
epidemiological statistics needed to improve or gain further insight into ototoxicity. WHO 
(2012) stated that there is a lack of epidemiological statistics on ototoxicity and hearing 
impairment in both developed and developing countries. Due to the lack of epidemiological 
statistics, it becomes apparent that it would be difficult to define the incidence and prevalence 
within a country and effectively have an impact on the rate or proportion of steps that need to 
be taken during ototoxicity.  However, before considering the impact of ototoxicity, one 
needs to understand what it is and what causes it.  
 
2.3. Ototoxicity 
Ototoxicity refers to a hearing loss or vestibular dysfunction that occurs from the use 
of ototoxic therapeutic drugs (Kramer, 2008). Ototoxic drugs are certain medications that 
have the potential to cause damage to the ear, either permanently or temporarily, which can 
result in hearing loss, tinnitus and/or balance disorders (Cone et al., 2011). The 
pathophysiology of ototoxicity implicates the destruction of the sensory hair cells in the 
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cochlea and vestibular labyrinths (Rotstein & Mandell, 2004). The hearing loss occurs as a 
result of the degeneration of the hair cells within the cochlea, which typically begins at the 
basal end and progresses towards the apex; thus, resulting in a high frequency hearing loss at 
the onset (Altena & Jager, 2002). There has, however, been discrepancy between the clinical 
observation of patients receiving aminoglycoside treatment complaints of developing a 
hearing loss and the reported incidence of hearing loss (up to 41%) (Altena & Jager, 2002). 
This discrepancy is most likely due to the patient not complaining of hearing loss until 
considerable auditory deficits occur; thus, emphasising the need for ototoxicity monitoring, 
as well as counselling on aspects related to ototoxicity (Altena & Jager, 2002). However, 
ototoxicity monitoring can only be possible if audiologists are aware of the conditions for 
which ototoxic medication is administered. The conditions, together with the type of 
medication as well as the names of the medication are indicated in Table 2.1., below.  
 
Table 2.1 
Common substances known to be associated with ototoxicity 
Type/Group 








infections, multi-drug resistant 
organisms, 
Tobramycin Bacterial infections of the eye or eyelid 
Neomycin Hepatic encephalopathy and hypercholesterolemia. 
Netilimicin Enterobacterial and pseudomonas infection 
Kanamycin 
Infections of the lungs, urinary tract, 
bones and joints, soft tissue, intra-
abdominal infections, meningitis, 
MDR-TB and septicaemia 
Amikacin 
MDR-TB, pseudomonas aeruginosa, 
acinetobacter, enterobacter, serratia 
marcescens and providencia stuartii 






Skin infections, bloodstream 
infections, endocarditis, bone and joint 




Bronchitis, diphtheria, legionnaires' 
disease, pertussis (whooping cough), 
pneumonia; rheumatic fever, venereal 
disease, and ear, intestine, lung, 
urinary tract, and skin infections 
Loop diuretics 
Furosemide and torsemide Congestive heart failure and edema. 
Ethacrynic acid 
High blood pressure and the swelling 
caused by diseases like congestive 
heart failure, liver failure, and kidney 
failure. 
Bumetanide Heart failure 
Chemotherapeutic agents 
Cisplatin  
Various types of cancers, including 
sarcomas, some carcinomas (e.g. small 
cell lung cancer, and ovarian cancer), 
lymphomas, and germ cell tumours 
Carboplatin  
Cancer of ovarian carcinoma, lung, 
head and neck cancers as well as 
endometrial, oesophageal, bladder, 
breast and cervical; central nervous 
system or germ cell tumours; 
oestrogenic sarcoma, and as 
preparation for a stem cell or bone 
marrow transplant. 
Nitrogen mustard Lymphoma  
Salicylates Aspirin Anti-inflammatory used to lessen the chance of cardiac arrest or stroke 
Anti-malarial drugs, 
environmental chemicals and 
other substances 
Quinine, chloroquine lead, 
tin, mercury, carbon 
monoxide, arsenic, carbon 
disulfide, hexane, toluene 
and alcohol 
Malaria and poisoning 
Table 2.1. Adapted from “Ototoxicity” by Virtual Medical Centre (2008), para. 1 
 
As indicated in Table 2.1., above, there are a large number of conditions which 





2.3.1. Tuberculosis and Multi-Drug Resistant Tuberculosis 
TB is an airborne disease caused by Bacillus Mycobacterium tuberculosis and is one 
of the leading infectious diseases in the world (WHO, 2012). “A relatively small portion of 
people infected with Mycobacterium tuberculosis will develop the TB disease; however, 
those individuals with Human Immunodeficiency Virus (HIV) have a higher probability of 
developing the TB disease” (WHO, 2012, p. 3). The TB disease typically affects the lungs; 
however, it may affect other sites, such as the larynx, the lymph nodes, the brain and the 
kidneys (WHO, 2012). There is known to be an increase in mortality rate if TB is left 
untreated (WHO, 2014). In addition, if TB is left untreated it may lead to the development of 
MDR-TB, which occurs when the treatment regimen of a TB patient is inadequate or 
incomplete, i.e. the patient could be defaulting on treatment regimens; thereby, allowing 
some of the stronger/resistant bacilli to survive and prosper (Castillo-Chavez & Feng, 1997). 
MDR-TB has, therefore, become an obstacle in many programmes and guidelines that have 
been developed for TB control (Duggal & Sarkar, 2007).  
 
Furthermore, Duggal and Sarkar (2007) suggested that the issues surrounding the 
origin of drug resistance are related to the length of treatment, specifically tolerability and 
adherence. Thus, incomplete and inadequate treatment regimens i.e. patients who default on 
their TB treatment schedule, are the most important factors that lends itself to believe that 
MDR-TB is a man-made problem (Duggal & Sarkar, 2007). Therefore, there is a need for 
stringent treatment regimens that will assist in the prevention and controls measures being 
conducted worldwide. However, despite recent advancements in global control efforts, TB 
remains a major public-health burden in most developing countries, including South Africa 




2.3.2. Epidemiology of TB and MDR TB 
South Africa, like many sub-Saharan countries, had an upsurge of TB cases over the 
past decade with the figures reported to have increased, despite improved efforts for the 
disease care and control (Khoza-Shangase, Mupawose, & Mlangeni, 2009). This is attributed 
to the alarming increase in co-infection rates with HIV and the result of low adherence to the 
treatment of TB in patients in South Africa (Bernard, 2011). After TB was declared a global 
health emergency by WHO in 1993, the mid-1990’s was a period of improved efforts for the 
disease care, prevention and control (WHO, 2012). However, TB still continues to be a major 
global concern, as in 2012 an estimate of 8.6 million people had developed TB, with there 
being 1.3 million fatalities from the disease (WHO, 2013).  
 
According to WHO (2012), South Africa was ranked one of the five countries with 
the largest number of TB cases reportedly at 0.4 million – 0.6 million (WHO, 2012). “The TB 
incidence rate at country level ranges substantially, with around 1000 or more cases per 100 
000 people in South Africa” (WHO, 2013, p. 11). There has been a 42% increase in detected 
cases eligible for treatment compared to 2011, with the largest increases between 2011and 
2012 noted in India, South Africa and Ukraine; with India and South Africa accounting for 
one-third of the global TB fatalities (WHO, 2013). Furthermore, the number of MDR-TB 
cases was on the increase with KwaZulu-Natal specifically being ranked as the province with 
the highest number of TB cases between the years 2004-2010 (Department of Health, 2011), 








Number of Patients with MDR-TB between 2004-2010 
Table 2.2. Sourced from “Multi-Drug Resistant Tuberculosis: A Policy Framework on Decentralised and 
Deinstitutional Management for South Africa” by Department of Health (2011), p. 4. 
 
The need for the development and implementation of policies in countries, such as 
South Africa, would assist in the reduction of the number of MDR-TB cases and prevent 
patients from defaulting on their treatment regimens (WHO, 2011). A high success rate of 
one such policy is the DOT policy (Direct Observed Treatment), as this allows for a high 
degree of patient compliance with treatment (Duggal & Sarkar, 2007). In 2013, less than 25% 
of MDR-TB cases were detected compared to the number of cases detected in 2012 (WHO, 
2013). This should indicate that the understanding of the concept of MDR-TB and increased 
awareness has helped. This would then lead to improved knowledge and skills base, related to 
the aminoglycosides used in the treatment of MDR-TB, among professionals that are 
involved in the management of patients with MDR-TB. 
 
2.3.3. MDR-TB and Aminoglycosides 
Aminoglycosides are used to treat many gram-negative bacterial, staphylococcal, and 
mycobacterial infections (Neely, 2008). Aminoglycosides are recommended, as they have a 
resilient action against various multi-drug resistant gram negative bacilli and are, therefore, 
 2004 2005 2006 2007 2008 2009 2010 TOTAL 
Eastern Cape 379 545 836 1092 1501 1858 1782 7993 
Free State 116 151 198 179 381 253 267 1545 
Gauteng 537 676 732 986 1028 1307 934 6200 
KwaZulu-Natal 583 1024 2200 2208 1573 1773 2032 11393 
Limpopo 59 40 77 91 185 204 126 782 
Mpumalanga 162 134 139 506 657 446 312 2356 
Northern Cape 168 155 188 199 290 631 353 1984 
North West 130 203 225 397 363 520 158 1996 
Western Cape 1085 1192 1179 1771 2220 2078 1422 10947 
South Africa 3219 4120 5774 7429 8198 9070 7385 45196 
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considered to be an important component in treating serious infections (WHO, 2008). The 
treatment that is vital in the management of MDR-TB are, “aminoglycosides (amikacin, 
kanamycin, capreomycin), fluoroquinolones (ciprofloxacin, ofloxacin, levofloxacin, 
moxifloxacin, gatifloxacin), old bacteriostatic second line anti-tuberculosis agents 
(ethionamide, protionamide, cycloserine, para-amino salicylic acid, thiocetazone) and anti-
tuberculosis agents with unclear efficacy (clofazimine, amoxicillin/clavuanate, 
clarithromycin, linezolid” (Duggal & Sarkar, 2007, p. 1473). The aminoglycosides (i.e. 
kanamycin, amikacin, capreomycin and streptomycin) are classified as a group 2 drug 
(meaning injectable drugs) by the World Health Organization (Seddon et al., 2012) 
 
The first line drugs that are used to treat TB are isoniazid, rifampicin, ethambutol and 
pyrazinamide. However, due to MDR-TB being resistant towards isoniazid and rifampicin, 
chemotherapy of the condition cannot rely upon the use of these medications and, therefore, a 
combination of second-line drugs may be used as a treatment option. Thus, depending on the 
individual susceptibility of the patient with MDR-TB, first-line oral drugs must be 
appropriately combined with second-line injectable aminoglycosides (Duggal & Sarkar, 
2007). A standardized treatment programme for all newly diagnosed patients with MDR-TB 
is recommended i.e. an intensive phase of six months, which includes injectable treatment 
consisting of five drugs; kanamycin or amikacin, levofloxacin, ethionamide, terizidone and 
pyrazinamide. These are taken at least six times per week during the injectable phase, 
followed by a continuation phase treatment with four drugs; levofloxacin, ethionamide, 
terizidone and pyrazinamide taken at least six times per week (DOH, 2010). Due to the use of 
a combination of the second-line drugs, the patient may be exposed to more side effects, as 
each drug presents with a different type of side effect (National Health and Medical Research 
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Council, 2008). In addition, the severity of cochleotoxicity and vestibulotoxicity varies 
among the different aminoglycosides (Jones, 2008), as indicated in subsequent discussions. 
 
Amikacin is a semi synthetic aminoglycoside i.e. prepared by chemical synthesis from 
natural materials, which acts against mycobacterium tuberculosis as well as atypical 
mycobacteria. It has primarily been known for cochleotoxicity (Taylor & Forge, 2006).  
Kanamycin is an antibiotic synthesized by streptomyces kanamyceticus, which has shown 
activity against mycobacterium tuberculosis; however, large doses of this aminoglycoside are 
needed, and thus the risk of ototoxicity and nephrotoxicity is increased (Duggal & Sarkar, 
2007).  
 
The next aminoglycoside, Capreomycin is an anti-microbial cyclic peptide that is 
capable of destroying or inhibiting the growth of micro-organisms, which is synthesized by 
streptomyces capreolus and is effective both in vitro and in experimental tuberculosis 
(Duggal & Sarkar, 2007). It has proven its value in the therapy of resistant tuberculosis as 
well as with the treatment failure of tuberculosis when given with ethambutol or isoniazid; 
however, similar to amikacin and kanamycin, capreomycin is ototoxic but the cost of therapy 
is substantially higher (Duggal & Sarkar, 2007).  
 
These second-line drugs, used in combinations, assist in the treatment of MDR-TB, 
which in turn has an added risk compared to that of first-line drugs. However, despite the 
risk, the use of aminoglycoside treatment has increased due to the rise in the incidence of 
MDR-TB (Harris et al., 2012). This, in turn, would result in an increase in the number of 
patients presenting with ototoxicity. In South Africa, a country where financial considerations 
play a major role in patient treatment and care, kanamycin or amikacin is more commonly 
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used in a clinical setting for treatment of MDR-TB, as it is considered to be the least 
expensive option (Taylor & Forge, 2006). There are financial constraints on health care 
systems in developing countries, such as South Africa due to the competing budgetary 
demands from life-threatening and/or communicable diseases (Harris et al., 2012). This 
shortfall has a great impact on services; the lack of funding greatly affects not only the 
coverage of services but also the quality of services that could be given to patients with 
MDR-TB. Due to these constraints, the use of kanamycin and amikacin will be higher, which 
could mean that the South African population could face an increase in the number of 
patients presenting with ototoxicity. 
 
While a systematic review of international studies revealed that the incidence rates of 
aminoglycoside-induced hearing loss ranged between 20% to 33% (Brummett & Morrison, 
1990). A study by Harris et al., (2012), revealed that 57% of their participants with MDR-TB 
presented with aminoglycoside-induced hearing loss. This highlights the need for an 
ototoxicity monitoring program in South Africa. However, in order for an audiologist to 
implement an effective ototoxicity monitoring program, s/he needs to fully understand the 
mechanism of the aminoglycoside induced toxicity. 
 
2.3.4. Mechanism of Aminoglycoside-Induced Ototoxicity 
It is suggested that about 25% of patients who are treated with aminoglycosides 
present with a toxicity (WHO, 2008). Aminoglycoside toxicities are known to affect mainly 
the kidney and ear, due to the drug concentration in the renal tubular cells and in the 
perilymph and endolymph of the inner ear (Roland & Rutka, 2004). Aminoglycosides are 
known for their toxicity to the eighth cranial nerve, i.e. both the vestibular and auditory 
branches; thus, resulting in ototoxicity (Altena & Jager, 2002). According to Roland and 
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Rutka (2004), the specific mechanisms of the hair cell toxicity is unclear; however, they are 
understood in the following steps: 
Step One: positively charged aminoglycosides are attracted to the negatively charged hair 
glycocalyx present on the apical surface of the hair cells, the aminoglycoside then attaches to 
the stereocilia, which competes with the calcium. This leads to a reversible interference with 
transduction channels (Roland & Rutka, 2004). 
Step Two: the entrance of the aminoglycoside into the cell is from the basal end and there is a 
biochemical machinery interference that occurs; however, the precise mechanism of this is 
hypothetical i.e. the attachment of the aminoglycoside to the phospholipids may or may not 
cause the membrane damage or interference with protein-producing cells (Roland & Rutka, 
2004).  
 “Aminoglycosides gradually accumulate in the endolymph and perilymph of the 
inner ear and the half-life in these fluids is 5 to 6 times greater than that of plasma half-life” 
(WHO, 2008, p. 2). Back-diffusion is reliant on the concentration of the aminoglycoside in 
plasma; hence, ototoxicity is more likely to occur in patients with persistently elevated 
concentrations in plasma (WHO, 2008). However, even a single dose can cause ototoxicity. 
The vestibular and cochlear sensory cells are prone to degeneration by aminoglycosides and 
the changes are largely irreversible (WHO, 2008).  
 
Injectable MDR-TB treatment has the ability to destroy the basal hair cells of the 
basilar membrane, which are required for high frequency hearing (Seddon et al., 2012). Thus, 
aminoglycoside–induced ototoxicity usually affects the high frequencies first, with later 
progression to the frequencies associated with speech communication (Seddon et al., 2012). 
According to Appana (2013), the high and ultra-high frequencies are most affected as 
treatment progressed; with the severity increasing from mild to profound. This suggests that 
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speech communication is greatly affected and that there is an increase to cochlea damage as 
treatment progressed. Damage to the hair cells is usually permanent. In addition, these drugs 
can also destroy the hair cells of the vestibule, resulting in vestibular deficits (Seddon et al., 
2012). These vestibular deficits include oscillopsia during head movements and postural 
instability (AAA, 2009). However, these symptoms may be experienced at later stages in 
treatment or after the cessation of aminoglycoside treatment (Haybach, 2002). 
 
According to Altena and Jager (2002), "ototoxicity does not appear until 5 days after 
the start of aminoglycoside treatment” (p. 262). However, not all reported cases of hearing 
loss may be due to ototoxic drugs; patients who are not receiving ototoxic drugs can have 
auditory changes that are considered to represent the established criteria for ototoxicity 
(Altena & Jager, 2002). Thus, the best way to manage ototoxicity is to identify it early and 
thereafter, take steps in order to prevent the progression of its effects, as appropriate changes 
can be made to the treatment regimen. This, therefore, emphasizes the need for audiological 
monitoring within the treatment regimen and consequently highlights the importance of the 
audiologist as part of the trans-disciplinary team managing the patient with MDR TB. An 
additional task of the audiologist would be the counselling of aspects such as the synergistic 
effects of ototoxic drugs and exposure to noise (Neely, 2008). Furthermore, the audiologist 
should be familiar with the risk factors associated with aminoglycoside-induced hearing loss, 
as it may assist with identification of at-risk patients as well as aspects of counselling that 
may need to be addressed. 
 
2.3.5. Risk Factors Related to Ototoxicity    
Jones (2008) reported that there is existence of specific patient risk factors for 
aminoglycoside ototoxicity which may be cochleotoxic or vestibulotoxic in nature, 
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irrespective of the ototoxicity mechanism. Gatell et al. (1987) indicated that the probability of 
developing ototoxicity ranged from 3% to 26%, as age increased from 14 to 90 years, whilst 
serum level, total aminoglycoside dose, duration of therapy, sex, peak temperature, presence 
of bacteria, shock, liver cirrhosis, renal failure, and development of renal toxicity did not add 
significantly to the prediction of auditory deficits. However, Moore, Smith, and Lietman 
(1984) reported that patients with auditory toxicity who had undergone aminoglycoside 
therapy for a longer duration were more likely to present with bacteremia and on average had 
a higher temperature; thus, indicating the possible sign and symptoms related to ototoxicity.  
 
In addition, many studies have identified a number of genes associated with 
aminoglycoside-induced hearing loss (Seddon et al., 2012). Although these genes are 
uncommon, they occur in at least 1% of the South African population. These genes include 
A1555G, 961delT+C, T1095c, c1494T and A827G. The A1555G mutation was first 
described to be the most common variant. Patients who have the gene can develop a hearing 
loss, even in the absence of aminoglycoside treatment (Bardien et al., 2009). If this gene is 
detected the clinician may consider the use of other drugs or more frequent monitoring of the 
patient (Seddon et al., 2012).  
 
In South Africa, there are genetic services that are available for various health 
purposes (Kromberg, Sizer, & Christianson, 2013). These services are usually offered at a 
tertiary level institution. The services include prenatal genetic diagnosis, diagnostic, 
predictive and carrier testing; and genetic counselling services (Kromberg et al., 2013). This 
does not relate to matters specific to aminoglycoside-induced hearing loss. However, 
although pharmacogenetic testing is not generally available, it is being introduced for the 
assessment of TB drugs (Kromberg et al., 2013). Presently, there are no genetic services 
21 
  
available in the rural areas, except for the outreach clinics that may refer to a secondary 
institution (Kromberg et al., 2013). Furthermore, when aminoglycosides are used in high 
doses, approximately 15% of all patients on the treatment who presented with hearing loss 
were found to carry the A1555G mutation (Nance, 2003). Conversely, Harris et al. (2012) 
reported that due to the rarity of mitochondrial mutations in the 12S rRNA (0.09% - 3.96%), 
genetic tendencies may be less likely to contribute to the risk of ototoxicity to be seen in 
developing countries. Audiologists, therefore, need to be cognizant of these factors, as it will 
allow the audiologist to identify the at-risk patients more effectively and timeously, which is 
considered to be one of the fundamental elements of ototoxicity monitoring, as indicated in 
ototoxicity monitoring guidelines by ASHA (1994). 
 
2.4. Current International Guidelines for Ototoxicity Monitoring 
ASHA (1994) developed a policy that outlined the guidelines used for the 
audiological management of individuals receiving cochleotoxic drug therapy. This policy 
clearly illustrated the role of the audiologist in the management of all ototoxic cases (ASHA, 
1994). This policy highlighted the following elements: 
 a specific criteria for identifying ototoxicity,  
 timely identification of at-risk patients,  
 pre-treatment counselling regarding potential ototoxic effects,  
 baseline measures (pre-treatment or early in treatment),   
 monitoring evaluations at sufficient intervals to document progression of hearing loss or 
fluctuation in sensitivity, and 




2.4.1. Specific Criteria for Identifying Ototoxicity 
The purpose of baseline testing is to establish and document the level of hearing prior 
to MDR-TB treatment (ASHA, 1994). The baseline audiogram is also needed as ototoxicity 
is determined by comparing the baseline to a subsequent result (Konrad-Martin et al., 2005). 
The criteria use to indicate a deterioration in hearing during ototoxicity monitoring are 
defined as,  
“(a) 20 dB decrease at any one test frequency, (b) 10 dB decrease at any two adjacent 
test frequencies, or (c) loss of response at three consecutive test frequencies where 
responses were previously obtained (the third criterion refers specifically to the 
highest frequencies tested, where earlier responses are obtained close to the limits of 
audiometric output and later responses cannot be obtained at the limits of the 
audiometer)” (ASHA, 1994, p. 6).  
In order for audiologists to provide accurate assessments and classifications of 
ototoxicity, clinical studies and reporting of clinical outcomes are essential, as ototoxicity 
grading scales need to be designed in a way that does not adversely affect the minor 
difference and or modifications in audiological protocols (Chang, 2011). Thus, it is crucial 
for an audiologist to understand the criterion that they would utilise, so as to make informed 
decisions on whether there has been a significant change in the patient’s hearing sensitivity 
during the course of the MDR-TB treatment. If no criterion is followed or adhered to, 
audiologists would not be able to identify or make clinically appropriate decisions when there 
are changes to a patient’s hearing status. Thus, it is important for audiologists to have explicit 
protocols to follow when conducting ototoxicity monitoring. Despite the lack of such 
protocols in South Africa, audiologists may still access international guidelines for the 




2.4.2. Patient Identification 
Patient identification is an essential aspect of managing ototoxicity and should be 
conducted as soon as possible (ASHA, 1994). However, hearing tests are usually conducted 
when the patient reports of communication difficulties, which would indicate that patients 
with MDR-TB would undergo a hearing assessment only once some degree of damage to the 
auditory system has occurred (Seddon et al., 2012). Patient identification can be efficiently 
conducted if the audiologist is aware of the associated risk factors such as the type, dosage 
and duration of the aminoglycoside used which, in turn, would indicate the need for 
ototoxicity monitoring. In South Africa, referrals to the audiology departments may be 
delayed due to the high HIV/AIDS co-infection rate as the focus may be placed on factors 
other than those related to hearing loss. Even though, hearing impairment may not be one of 
the major concerns, documentation or capturing of data on each patient would allow for 
better referral to the relevant health professional. According to Avent, Rogers, Cheng, & 
Paterson (2011), the monitoring of aminoglycosides is conducted via computerised methods 
in Australia; however, it was discovered that not all hospitals had access to computers and 
thus, means of providing access was reviewed. Therefore, the new policy implemented in 
Australia indicates that information related to monitoring should be captured only via 
computerised methods (Avent et al., 2011). Thus, databases which would allow medical 
professionals to access patients’ medical history are important. 
 
According to Nglazi et al. (2012), there are at least four data sources available in 
South Africa which collect information on the patients who have TB and/or HIV:  (1) eKapa 
TB and ART database, currently being used in in the Western Cape clinics since 2009, which 
gathers information regarding demographics, clinical information, number of visits for TB/ 
HIV treatment and patient outcomes; (2) Paper-based TB registration/ the electronic version 
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(ETR.net), which is able to monitor TB treatment; (3) National Health Laboratory Services 
(NHLS) database; and (4) Patient records. These databases for both TB and/or HIV allow for 
a unique way of identifying patients in need of ototoxicity monitoring and should make the 
referral process to audiology departments in South Africa more efficient. These databases 
would be successful; especially if aspects related to ototoxicity monitoring would be 
documented. This would allow for access to patient information regarding their baseline 
and/or monitoring results easier to view, especially if baseline and follow-up evaluations are 
conducted at different institutions. However, access requires technological equipment that 
may not be readily available to some audiologists. In addition, the reliability of the results 
may be questioned due to the lack of a standard protocol for audiological monitoring in South 
Africa. However, any modifications made to recommended protocols could also be captured 
in the database for the audiologist to understand. This would then assist in providing efficient 
therapy for patients with MDR-TB, which usually begins with pre-treatment counselling. 
 
2.4.3. Pre-treatment Counselling 
Pre-treatment counselling should be conducted prior to administration of treatment. 
The physician needs to include information regarding the risks and benefits of the treatment 
and thereafter, the audiologist should counsel the patient of any cochlea or vestibular problem 
that may occur, as well as the possibility of communication difficulties (ASHA, 1994). The 
audiologist should also counsel the patient on the usual signs and symptoms of hearing loss, 
the need for communication strategies and the synergistic effect of noise exposure and 
ototoxic drugs (Konrad-Martin et al., 2005). All these aspects are addressed during pre-
treatment counselling because the audiologist is ethically bound to provide information on the 
adverse effects and outcomes of treatment (AAA, 2009). However, this may not be 
established if the medical team viz., the physicians and nursing staff do not understand what 
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ototoxicity is or the importance of audiological services to a patient with MDR-TB, as has 
been demonstrated by Khoza-Shangase (2013). Therefore, it is imperative that the health 
professionals involved in the management of a patient with MDR-TB, be in-serviced about 
the ototoxic effects of aminoglycosides and ototoxicity monitoring in this patient population 
(AAA, 2009).  
 
In South Africa, counselling may be challenging due to the language barrier between 
the patient and the audiologist, as patients need to ideally be counselled in their first language 
(van Dyk, 2008). There are currently eleven official languages in South Africa, including 
English, Afrikaans, Ndebele, Northern Sotho, Sotho, Swazi, Tswana, Tsonga, Venda, Xhosa 
and isiZulu; however, most audiologists in South Africa are trained at University in English 
or Afrikaans. They would, therefore, require the assistance of a translator, who would be able 
to rephrase the information to make it understandable for the patient (van Dyk, 2008). 
Nevertheless, the audiologist needs to be aware of the problems they would encounter by 
using a third person in the counselling process (van Dyk, 2008). Often, the translator may 
rephrase according to their own frame of reference, which may add prejudice or their own 
experiences to the information they impart to the patient. Therefore, accurately translated 
informational pamphlets or brochures should also be available so as to ensure that the correct 
information is imparted to the patient (van Dyk, 2008). However, the use of pamphlets, 
brochures or informational guides may also prove to be challenging, if they are not be 
suitable for the literacy levels of the patient. According to Statistics South Africa (2011), 
nationally there has been a significant reduction in the percentage of individuals who are 
functionally illiterate, from 33.6% in 1996 to 19.1% in 2011. However, there is still much 
concern on the literacy rates of the patients; thus, proving that some of the material used by 
audiologists may be impractical. In light of these challenges South African audiologists, 
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therefore, make provisions in order to overcome these challenges such as including the family 
or friends of the patient in the pre-treatment counselling and assessment or consider the use 
of visual aids. However, the use of family members and friends has been discouraged, due to 
the emotional ties that they have, as well as, their lack of knowledge pertaining to the 
information being imparted (Kale & Syed, 2010), indicating that although it may work in 
order to relay information, one needs to be aware of the consequences such as incorrect 
information and innuendo. 
 
2.4.4. Baseline Assessment 
Patients with MDR-TB, who are receiving aminoglycosides should have baseline 
assessments conducted prior to or within 72 hours of initial treatment (ASHA, 1994). The 
HPCSA guidelines indicate that patients with HIV/AIDS and TB need to have baseline 
assessments within 24 hours of initiation of ototoxic medication. In New Zealand, 30.4% of 
patients who receive ototoxic medication did not undergo baseline assessment prior to 
initiation of their treatment (Alchin, 2010). Therefore, it is evident that in some institutions, it 
may not always be possible to conduct the audiological evaluation within the 72 hour 
window; possibly due to lack of staff or time constraints within the audiology department 
(Busacco, 2009). However, this needs to be conducted in order to document the progression 
of the possible hearing impairment by utilising the baseline results to compare to periodic 
results obtained.  
 
The baseline assessment includes an in-depth case history with a particular focus 
placed on the medical history of any auditory and vestibular difficulties, family history of 
ototoxic hearing loss, recent ototoxic medications taken and any recent exposure to noise or 
radiation (ASHA, 1994). Thereafter, the patient will undergo the following tests during 
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baseline assessment; otoscopic examination, immittance audiometry, pure-tone audiometry, 
speech audiometry, as well as, OAEs and/or ABR. Al-Malky, Dawson, Sirimanna, Bagkeris, 
and Suri (2014) indicated that the use of HFA and DPOAEs have shown an increased 
sensivitity for the early detection of an ototoxic drug-induced hearing loss. This test battery 
may be modified according to the attentiveness of the patient and are thus categorized 
accordingly into three groups i.e. responsive, limited response and unresponsive patients 
(ASHA, 1994).  
 
Responsive patients are able to provide reliable behavioural responses; while limited-
responsive patients can provide reliable behavioural responses only for short periods of time. 
This could be due to illness, physical conditions, or age-related factors. However, 
unresponsive patients cannot provide reliable behavioural responses and can only be 
evaluated with objective measures that do not rely on responsiveness or attentiveness 
(ASHA, 1994). Responsive patients undergo a full audiological evaluation, as they are able to 
provide a behavioural response (ASHA, 1994). However, this test battery needs to be 
modified for those patients with limited responsiveness in order to accommodate the needs of 
the patient, so as to obtain the most essential information. Thus, according to the ASHA 
(1994) guidelines, objective means of testing should be used to test those patients with 
limited responsiveness or unresponsive patient. These include OAE and ABR testing. OAE 
testing has been shown to be the most reliable means of detecting early cochlear outer hair 
cell damage (Mattucci & Vasquez, 2003). However, abnormal middle-ear function and 
baseline hearing loss of greater than 40 dB HL may preclude effective monitoring using 
OAEs (Mattucci & Vasquez, 2003). Therefore, ABR testing may be more appropriate for 
such cases (Mattucci & Vasquez, 2003). According to the HPCSA (2007), the use of OAEs 
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and ABR is a preferred method of audiological assessment for patients (adult or child) who 
are unable to respond during the behavioural method of testing.  
  
In addition, while patients who are classified as responsive and limited-responsive 
may be able to respond during behavioural testing, the test battery needs to be conducted 
quickly and effectively, as these patients generally fatigue easily. When conducting pure tone 
audiometry that includes test frequencies from 9 kHz to 20 kHz, the duration of the 
evaluation can be lengthy, and may thus present as a challenge for patients who are ill, as it 
may affect the ability of the patient to respond reliably (ASHA, 1994). Thus, it is 
recommended that testing commence at the higher frequencies and thereafter, depending on 
patient reliability, move to the lower frequencies (ASHA, 1994). It is important to note that 
although it may be recommended that testing commence at higher frequencies, all test 
frequencies need to be evaluated in order to understand and document changes in the auditory 
system (AAA, 2009).  
 
However, Fausti et al. (1992) indicated that there has been higher incidence of 
ototoxicity when utilizing high frequency audiometry (HFA) and it is, therefore, valuable in 
the early detection of ototoxicity. HFA encompasses air conduction threshold testing for the 
frequencies above 8000 Hz, ranging up to 16 or 20 kHz (AAA, 2009). It permits the detection 
of aminoglycoside-induced or cisplatin-induced ototoxic losses well in advance, even before 
changes are noticed in the conventional frequency range used in audiometric testing due to 
the effects of the drugs, which tend to affect the basal end of the cochlea first (AAA, 2009).  
 
According to Konrad-Martin et al. (2005), HFA has good test-re-test reliability and 
low false positive rates, and is, thus, recommended to be an ideal test that may be used for 
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reliable and sensitive ototoxicity evaluation (ASHA, 1994).  However, despite there being 
much controversy surrounding the use of HFA, it is now well established and widely used in 
many departments (AAA, 2009). Hesitance to use HFA arose from the concern for excessive 
inter-subject variability of the threshold measure, due to the problem of standing waves in the 
ear canal above the resonant frequency (AAA, 2009). This, however, has deteriorated over 
the years due to the advancements in instrumentation (AAA, 2009); therefore, suggesting that 
HFA is becoming a widely acceptable practice for audiological management of patients, as 
HFA would be able to provide vital information for ototoxicity. However, considering the 
constraints that many South African audiology departments face, such as the lack of 
appropriate equipment (Koekemoer & Ndjeka, 2013) and adequate staff, it is likely that HFA 
audiometry is not routinely conducted in ototoxicity monitoring.  
 
However, there has been a distribution of 38 mobile monitoring systems across the 
country of the high frequency audiometer known as the KUDUwave (Koekemoer & Ndjeka, 
2013). This portable system has been used to conduct audiological monitoring for patients 
undergoing ototoxic treatment and is able to detect high frequency hearing losses. This would 
allow for an increase in decentralised management of a patient with MDR-TB from the onset 
of treatment (Koekemoer & Ndjeka, 2013); consequently, resulting in improved service 
delivery and management of a patient with MDR-TB. Although, 38 mobile monitoring 
systems have been distributed, this does not sufficiently cover all areas in South Africa that 
are affected by MDR-TB as the incidence rate of this disease is extremely high. However, the 
results of these tests need to be captured accurately, as the KUDUwave can be used by other 




Furthermore, there is a need to assess tinnitus and dizziness at the outset of treatment 
with aminoglycosides, as it would assist with monitoring the progression of these side effects 
(Konrad-Martin et al., 2005). However, no formal guidelines have been developed to provide 
a monitoring procedure for tinnitus. Hence, it is recommended that the patient be questioned 
about their tinnitus at each monitoring assessment, so as to have comparative information 
(AAA, 2009).  
 
Similarly, there are no specific guidelines for the assessment of vestibulotoxicity 
(AAA, 2009), but assessments that may be used to assess vestibular function include 
electronystagmography testing (ENG), rotational testing, vestibular autorotation testing 
(VAT), vestibular evoked myogenic potentials (VEMPs) and computerized dynamic 
posturography (CDP) (AAA, 2009). There are also bedside assessments that can be used to 
identify bilateral peripheral vestibular system impairments. These include head-thrust and 
dynamic visual acuity tests. However, these informal tests are sensitive to impairments of 
high-frequency function and ototoxic medication begins to affect the high frequencies first, 
which indicates a possible concern for audiologists who attempt beside balance assessments; 
as these tests may not be helpful in the identification of bilateral peripheral impairments 
(AAA, 2009).  
 
However, vestibular tests are not widely available in South Africa and are usually 
found in specialised facilities (Rogers & Petersen, 2011). In addition, the personnel required 
generally have to be specially trained, experienced and competent individuals in vestibular 
testing (Rogers & Petersen, 2011). Therefore, some facilities are not adequately equipped or 
designed for optimal testing and more common than not, there is rarely trained staff available 
to conduct testing. The constraints experienced by audiology departments in South Africa, 
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may delay audiological monitoring and essentially the overall management of the patient. 
Thus, there is a need for more audiological services to be available at hospitals and primary 
health care centres, so as to allow for easier access to audiological services by patients 
requiring assessment and management. This, therefore, highlights the need for standardised 
programs or improved referral systems to enable audiologists to provide the best services to 
patients with MDR-TB. 
 
 Standardising the assessment of hearing for patients on treatment for MDR-TB is 
very important, as it will improve clinical case management within the TB program (Seddon 
et al., 2012). Every guideline should include the schedule, duration and testing method to be 
applied, as well as, the documentation of the configuration of the hearing loss to ensure that 
an informed decision can be made regarding clinical management (Seddon et al., 2012). An 
informed decision can be made easily or more efficiently if a patient adheres to the 
appropriate treatment regimen designed for them, which then allows the audiologists to 
prepare and schedule timeframes in order to provide follow-up evaluations needed 
throughout the ototoxicity monitoring process. 
 
2.4.5. Ototoxicity Monitoring  
A stringent monitoring evaluation should be conducted every 2-3 days a week as this 
will allow for early detection of hearing loss (Fausti et al., 1992). However, this is not always 
feasible; thus, it was recommended that follow-up assessments be conducted prior to each 
course of treatment i.e. most likely to be monthly (AAA, 2009) or follow-up evaluations are 
performed 24 hours prior to each course of treatment so as to allow time for any temporary 
threshold shift to recover (Langer, am Zehnhoff-Dinnesen, Radtke, Meitert, & Zolk, 2013). 
According to Venter (2011), 31% of patients receiving ototoxic treatment, do not have 
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follow-up assessments conducted during or after treatment in New Zealand. Watson and 
Selvadurai (2011) reported that patients who are currently receiving aminoglycosides should 
be monitored weekly, especially if treatment is more than or equal to 21 days. Alternatively, 
they may be assessed before each successive dose of treatment is administered.  
 
A monitoring test battery comprises of the same audiological tests used during 
baseline audiometry. This test battery is usually used for patients who are responsive during 
behavioural testing. Patients who have limited responsiveness or patients who are 
unresponsive undergo objective means of testing i.e. OAE’s or ABR (ASHA, 1994). Thus, 
information obtained from the OAE or ABR can be used to determine if there is a need for 
changes to be made to the patient’s treatment regimen. However, a study by Seddon et al. 
(2012) indicated that access to ABR and OAE were most likely to be in specialised 
institutions; highlighting the importance of health professionals to develop an effective 
referral system to these specialized audiology departments. The need for ototoxicity 
monitoring is important; however, there is a greater need for monitoring protocols to be 
sensitive and reliable for the early detection of ototoxicity in the least amount of time and 
also allow for routine monitoring to be conducted on more patients, especially in institutions 
that may not have specialized equipment (Vaughan et al., 2002).  
 
According to the HPCSA (2014), audiology departments at specialised TB hospitals 
in South Africa should have the following equipment for diagnostic hearing assessment; 
otoscopic examination, immittance measures, pure tone audiometry (air & bone conduction, 
un-& masked), high-frequency pure-tone audiometry, visual reinforcement audiometry, 
speech audiometry (un- & masked) and OAEs. However, the HPCSA guideline states that for 
ototoxic threshold shift monitoring, only high frequency air conduction pure-tone audiometry 
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and collaboration with doctors administering treatment should be conducted for patients 
undergoing ototoxic treatment (HPCSA, 2014). Although, this guideline indicates a standard 
to which audiologists need to conform to, it shows that there is a difference, compared to that 
of international protocols, in assessment of a patient who is undergoing ototoxic treatment. 
However, similar to the HPCSA guidelines is the monitoring protocol of the sensitive range 
for ototoxicity (SRO). This monitoring protocol is individualized to each patient’s hearing 
configuration where, the highest frequencies with a threshold less than or equal to 100dB 
SPL would be tested, followed by six lower adjacent frequencies. This is known as the 
sensitive range for ototoxicity (SRO) (AAA, 2009).  
 
SRO improves clinical efficacy by decreasing the test time; however, if there are 
notable changes in hearing sensitivity, it is recommended that a full test battery be conducted 
(Fausti et al., 2003). According to Fausti et al. (2003), 90% of the initial ototoxic hearing 
changes were detected by the use of SRO. This would indicate that if there is a shorter 
protocol which is able to assist an audiologist in identifying early changes to hearing it would 
be of great benefit. Once the aminoglycoside treatment is complete, the audiologist will need 
to advise the patients that they need to return for post treatment evaluations, aural 
rehabilitation and post treatment counselling. 
 
2.4.6. Long Term Follow-up  
The outcomes of post treatment evaluations would allow the patient to communicate 
effectively and/or adapt to adverse situations that the patient may be involved in with regard 
to communication ability and to identify hearing loss that is of late onset. Anecdotal 
experience revealed that post treatment management is one of the least practiced aspects of an 
ototoxicity monitoring program, as most audiologists may not have the time due to large 
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caseloads. According to Naidoo (2006), both private (70%) and public (90%) sectors provide 
auditory training, private (6%) and public (21%) provide speech reading, private (14%) and 
public (85%) provide language therapy and private (13%) and public (10%) provide manual 
communication. Audiologists may only perform a hearing aid fitting, which is considered to 
be a minute aspect of post treatment management. This indicates that there is a need to 
establish specific aspects that need to be addressed when providing post treatment 
management.  
 
Long-term audiological follow-up is important as it will enable the audiologist to 
determine if the hearing loss is stable or progressive in nature (ASHA, 1994). The audiologist 
needs to be aware that the use of aminoglycosides can also cause delayed hearing loss 
(Campbell, 2011). Therefore, follow-up testing should also be scheduled a few months after 
drug discontinuation (AAA, 2009). Follow-up evaluations should be conducted immediately, 
at 3 months, 6 months and 1 year after cessation of MDR-TB treatment (Konrad-Martin et al., 
2005). However, according to the HPCSA guidelines in South Africa, audiological 
intervention may be required until 6 week to at least six months depending on the type of 
ototoxic medication (HPCSA, 2014). According to Konrad-Martin et al. (2005), if the 
audiologist observes threshold changes during post treatment evaluations further monitoring 
is warranted until the hearing threshold is stabilized. Due to the changes in hearing 
sensitivity, weekly monitoring assessments should commence until hearing stabilizes 
(ASHA, 1994).  If hearing stabilizes at a level significantly worse than the baseline, a 
complete audiological test battery is recommended (ASHA, 1994). Therefore, it is essential 
for the audiologist to counsel the patient, as well as their family members, to keep them 
informed during each aspect of post treatment. This will allow the patient and their family 
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members to understand the outcomes of MDR-TB treatment; thus, enabling them to cope 
with the changes that may take place.  
 
There are three phases in counselling a patient undergoing MDR-TB treatment i.e. the 
initial phase, the post treatment phases and six month precautionary phase (Konrad-Martin et 
al., 2005). The initial phase is used to educate the patient on the potential adverse effects that 
the ototoxic medication may have on their auditory system and to establish any family history 
of aminoglycoside use (Konrad-Martin et al., 2005). The post treatment phase addresses 
aspects relating to the changes in hearing sensitivity and all other aspects related to their 
individualized aural rehabilitation program that would be beneficial to the patient when 
communicating (Konrad-Martin et al., 2005). The six month precautionary phase emphasizes 
the importance of hearing protection during and following treatment for at least six months 
(Konrad-Martin et al., 2005). Those patients who exhibit permanent hearing loss and/or a 
vestibular problem need to be referred; once again placing, the importance on a well-
functioning referral system.  
 
However, the lack of knowledge of the symptoms may hamper identification and 
subsequently have a negative impact on the appropriate referral and management of hearing 
loss (de Andrade, Khoza-Shangase, & Hajat, 2009). This in turn, impacts on the services that 
an audiologist can provide to the patient (Khoza-Shangase et al., 2009). As in the case of 
South Africa, counselling may occur during each visit to the audiologist and especially during 
follow-up treatment. The counselling would centre on the synergistic effects of noise and 
ototoxic treatment and would also impart that the effects of the ototoxic medication can last 
up to 18-24 months (Harris & Heinze, 2013).  In South Africa, follow-up assessments occur 
at 1 month, 3 months and 6 months after completion of treatment; thereafter, the main focus 
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is place on amplification or communication strategies that the patient could possibly utilise 
(Harris & Heinze, 2013).  
 
2.4.7. Aural Rehabilitation 
If an ototoxic hearing loss results in communication deficit, the audiologist is 
ethically bound to begin aural rehabilitation (i.e. hearing aid evaluation, hearing aid fitting, 
assistive listening devices, speech-reading, audition, etc.) (ASHA, 1994). The audiologist is 
responsible for implementing an aural rehabilitation plan that is specific to the needs of the 
patient (ASHA, 2011). In the audiological management of an adult, the focus is placed on re-
teaching the patient skills that have been hindered due to the hearing loss, helping the patient 
live with the hearing loss, optimize the use of amplification available, explore the needs of 
assistive listening devices, and teaching the patient communication strategies to overcome 
communication deficits (ASHA, 2011). The effects of an acquired hearing loss can be 
minimized by optimal use of amplification and a personalized aural rehabilitation program 
(Pienaar, Stearn, & Swanepoel, 2010).  
 
According to a survey by Pienaar et al. (2010) patients who were hearing impaired 
and fitted with hearing aids were satisfied by its benefits even if the hearing aid fittings were 
not optimal; thus, the findings of the study advocate for the initiation of sustainable aural 
rehabilitation services in developing countries such as South Africa. Furthermore, the study 
indicated that counselling remains to be an essential aspect of an aural rehabilitation program; 
thus, indicating the need for audiologists to develop and implement an aural rehabilitation 




Aural rehabilitation forms an integral part of the audiological management of patients 
with MDR-TB, as has been stipulated in the ASHA (1994) and AAA (2009) ototoxicity 
monitoring guidelines. AAA (2009) position statement and ASHA (1994) clinical practice 
guidelines for ototoxicity monitoring and the audiological management of individuals 
receiving ototoxic and/or vestibulotoxic drug therapy guidelines, assist audiologists in 
implementing appropriate ototoxicity monitoring regimes; however, these guidelines are not 
based in the South African context and thus, can only serve as a guide to South African 
audiologists. The only context-relevant guidelines available to the South African audiologist 
are the policy developed by the South African National Department of Health (DOH, 
Management of Drug-Resistant Tuberculosis: Policy Guidelines, 2010) and the guidelines 
developed by HPCSA (A guideline for planning STA services at all levels of health care, 
2014). 
 
2.5. Current Guidelines for South African Audiologists 
The policy developed by the Department of Health (2010), is intended for use by 
healthcare professionals involved in the medical management of patients with MDR-TB 
(DOH, 2010). It focuses on clinical management, referral mechanisms and models of care, 
psychosocial support to ensure prevention and control, as well as, occupational health 
services that need to be available to patients with MDR-TB (DOH, 2010). This policy 
indicates the need for uninterrupted supply of appropriate medication and stipulated that 
medical treatment should be conducted under direct supervision with suitable education and 
counselling (DOH, 2010). The management of MDR-TB is a progressive approach, which 
needs to be revised through evidence-based information (DOH, 2010). Supervision of this 
treatment regime should be conducted by a medical team, usually consisting of the following: 
physician, professional nurse, pharmacist, social worker, psychologist, physiotherapist and 
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audiologist (DOH, 2010). Therefore, the policy gives audiologists an outline of the process 
involved in the management of a patient with MDR-TB, as indicated in the Figure 2.1, on the 
next page. 
Figure 2.1. Flow diagram indicating the process of managing hearing loss in patients with MDR-TB. Sourced 
from “Management of Drug-Resistant Tuberculosis: Policy Guidelines” by Department of Health, 2010, 
Department of Health¸ p. 77. 
 
The Department of Health policy indicates some aspects relevant to ototoxicity such 
as the need for baseline assessment; however, it does not reveal the test battery used for basic 
audiological testing or even ototoxicity monitoring. Thus, it would indicate that there is a 
need for the Department of Health to review and/or amend the audiological aspects of the 
current policy to ensure that audiologists across the country have standardised and more 
specific guidelines to follow in the audiological management of the patients with MDR TB.  
 
The current HPCSA guideline was developed so as to facilitate rehabilitation service 
planning and implementation at all levels of health care. The guidelines contain aspects 
related to audiological management of a patient undergoing ototoxic treatment. This 
guideline is not specific to the assessment and/or management of the patient with MDR-TB. 
However, it does advise audiologists to be aware of the indicators related to ototoxicity, such 
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as, the percentage of baseline audiograms completed upon initiation of ototoxic medication 
(i.e. within 24 hours), percentage of patient with signs or symptoms related to ototoxicity, 
patients who received medical intervention within 24 hours and audiological intervention at 
least 6 weeks post cessation of ototoxic treatment. Furthermore, the guideline goes on to 
describe the different levels of care at the different institutions such as a CHC, etc. In 
addition, the guidelines do not mention pre-treatment counselling or the topics that need to be 
addressed during this crucial time in the management of a patient with MDR-TB. This 
guideline fails to provide audiologists with the specific test battery to utilise when conducting 
ototoxicity monitoring or how to assess patients who may be non-responsive. Moreover, the 
guideline does not mention aspects related to post treatment management with the exception 
of hearing aid fittings and only follow-up evaluations at specialised TB hospitals. While, this 
guideline serves a purpose of making speech therapists and audiologists aware of the services 
that are needed at the different levels of care, it is evident that specific guidelines for 
ototoxicity monitoring is needed, as Harris et al. (2012) indicated that the need for context 
relevant tools and guidelines should not be left ignored but rather acknowledged. 
   
 According to Naidoo (2006) many institutions, both public and private, may make 
modifications or not conduct all audiological assessments due to time constraints, lack of 
qualified staff or understaffed departments, lack of equipment, language barriers and the 
quantity of the caseloads. The researcher postulates that to overcome constraints experienced 
in audiology departments, changes are made to monitoring protocols such as, conducting 
monthly assessments instead of doing them biweekly, as well as only conducting air 
conduction testing or only testing the high frequencies. Hence, there is a need for the 
establishment of protocols for ototoxicity monitoring in South Africa that would allow the 
audiologist to achieve sensible and reliable results in a short period of time, which allows for 
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routine assessment to be conducted without having to implement any modification to the 
norm.  
 
Seddon et al. (2012) reported that the proportion of patients with hearing loss seemed 
to be greater in programs where standardized hearing assessments have been conducted. This 
could indicate that clinically non-significant hearing loss is being detected when a 
standardised methodology is being used or that a larger number of patients with hearing 
losses are being missed when less robust assessments are being carried out. This suggests that 
the patients who undergo standardised methods of treatment benefit more with regard to 
hearing as it would be monitored from commencement of treatment and not when irreversible 
damage to the auditory system has occurred. There has been a notable lack of consensus 
amongst all current guidelines (Seddon et al., 2012). Although there are international 
guidelines available, there are no explicit contextually relevant guidelines for South African 
audiologists to utilise and it is important for audiologists to know that they are ethically 
obligated to follow evidence based best practice guidelines. This, therefore, serves as an 
impetus for the current study.  
 
There is also a need for further investigation on the management of hearing loss in a 
patient with MDR-TB, as there are no specific guidelines or protocols for South African 
audiologists to use as a foundation in the audiological management of a patient with MDR-
TB. Once an ototoxicity monitoring program is put into place, it will allow for early 
identification and appropriate changes to be made to the treatment regimes. Audiological 
management of hearing loss will be conducted at the early stages of deterioration and thus 




Furthermore, the findings of this study may help motivate for a more in-depth DOH 
and HPCSA ototoxicity monitoring policy, allowing for uniformity among audiologists in TB 
clinics in South Africa as the current policies are not explicit, in the assessment of a patient 
undergoing ototoxic treatment, such as, the audiological tests that are needed, the intervals in 
which to conduct assessment or the post treatment management of a patient. Furthermore, the 
availability of explicit guidelines specific for ototoxicity monitoring based in the South 
African context will assist in the interpretation of changes in hearing sensitivity will improve; 
thus, allowing for changes to treatment regimens to occur timeously and documentation of all 
stages of ototoxicity monitoring may assist in understanding the modifications being made in 
audiology department across South Africa and how it may improve service delivery. 
 
2.5.1. Service Delivery and Its Impact on Audiological Services 
Delivery of audiological services in South Africa has deteriorated, due to the many 
challenges faces by audiologists (Naidoo, 2006).  These challenges include limited budget 
allocated to audiological services, poor understanding or awareness of the services provided 
by audiologists, by other healthcare professionals and general public (Naidoo, 2006). 
According to HPCSA, primary health care centres, community health care centres should be 
providing ototoxicity screening in South Africa. Furthermore, audiologists at district 
hospitals, regional hospitals, provincial/central hospital should be able to conduct baseline 
assessments and monitoring for ototoxicity (HPCSA, 2014); while, audiologists at specialized 
TB hospitals should be conducting baseline assessments and high frequency testing (HPCSA, 
2014). However, delivery of audiological services is hindered by the lack of equipment, lack 
of training and lack of staff (Naidoo, 2006). According to Naidoo (2006), 59.14% in the 
public sector conduct ototoxicity monitoring, while in the private sector 54.79% conduct 
ototoxicity monitoring in South Africa. This suggests that approximately 40% of audiology 
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departments are not conducting ototoxicity monitoring which is alarming. Although, there are 
constraints that affect the audiological services for ototoxicity monitoring, audiologists have 
to overcome these barriers. According to Koekemoer and Ndjeka (2013), approximately 5000 
patients per month, require ototoxicity monitoring in South Africa and on average that is 
around 12 tests per patient. Audiologists have used methods such as tele-audiology to provide 
services to patients who may not have access to audiological monitoring or have made 
modifications to the recommended guidelines in order to provide the best possible service to 
the patient. This indicates the need for standardized regimens that are context-relevant to 
audiologists.  
 
In addition, WHO (2004) reported that healthcare systems need to be regularly 
assessed, in order to ensure that service delivery is of an acceptable standard.  Therefore, the 
present study aims to describe the current practices employed by audiologists in the 
management of patients with MDR TB.  According to Fagan and Jacobs (2009), there is a 
large disparity in the healthcare services between developing African nations and developed 
countries.  However, South Africa is on its way to achieving a level of healthcare that is 
similar to those associated with developed countries, through the development and 
implementation of various white paper policies.  In the meantime, there are audiologists who 
are practicing in a way that allows for maximizing of resources in an effective manner to 
ensure a high quality of healthcare. Ototoxicity monitoring protocols have been developed 
internationally and may, therefore, not be appropriate for the South African context. Often, 
adaptations to international protocols make them contextually relevant. This study, therefore, 
aims to document these practices so that the information can be used to devise contextually 





MDR-TB has become a global concern as it has impacted on the combat against TB 
(WHO, 2011). This chapter provided a description of TB and the development of MDR-TB. 
The literature review emphasized the need for guidelines and protocols, so as to provide a 
foundation to the audiologist, as this will improve services and efficiency of referrals between 
healthcare professionals. This chapter indicated the limitations of the South African health 
care system, compared to that of international standards with regard to the audiological 
management of a patient with MDR-TB.   Furthermore, the policy guidelines of the DOH and 
HPCSA for management of patients with MDR-TB require more in-depth information so as 







This chapter provides a description of the methodology utilised in the study. It 
includes the aims and objectives of the study, the study design, a description of the study 
population, sampling technique used, data collection instruments and the procedure used to 
collect the data.  Furthermore, a description of how the data was analysed, is highlighted.  In 
addition, issues relating to the validity and reliability of the study, as well as the ethical and 
legal considerations are also discussed. 
 
3.2. Aim and Objectives 
3.2.1. Aim 
To describe the audiological practices employed by audiologists in the management 
of adult patients with MDR-TB in South Africa. 
 
3.2.2. Objectives 
 To describe the specific criteria used for identifying ototoxicity, and the pre-treatment and 
baseline audiological practices employed by audiologists in South Africa. 
 To describe the ototoxicity monitoring protocols, post treatment and audiological 






3.3. Critical Assumptions 
It was assumed that the audiologists in South Africa make modifications to the 
recommended AAA (2009) and/or ASHA (1994) guidelines for ototoxicity monitoring in the 
management of a patient with MDR-TB. 
 
3.4. Study Design 
A descriptive survey design was used in the study with quantitative methods of 
analysis. This study design was used, as it allowed the researcher to learn about the target 
population by asking relevant questions and analysing their responses using frequencies and 
basic statistics (Leedy & Ormrod, 2005). A survey design provides quantitative data on the 
trends, attitudes, or the opinions of a population by studying the sample population (Creswell, 
2003). The researcher is then able to use the results of the sample to generalise or make 
claims about the population (Creswell, 2003).   
 
A survey was used to attempt to provide descriptions of the audiological practices 
employed by audiologists in the management of adult patients with MDR-TB in South 
Africa.  A descriptive quantitative research encompasses distinguishing the characteristics of 
an observed phenomenon or investigating possible correlations amongst two or more 
phenomena (Leedy & Ormrod, 2005). This design was appropriate for the current study 
because it provided answers to questions, which enabled the researcher to achieve the 
objectives of this study. 
 
3.5. Study Population 
The study population comprised of the 1632 audiologists in South Africa. 
Audiologists were selected, as the focus of this study was to describe the audiological 
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practices employed by audiologists in the management of adult patients with MDR-TB in 
South Africa. Audiologists from the private and public schools and hospitals, were targeted 
as the researcher could not assume that if an audiologist is currently working at a school, the 
audiologist does have not have any recent experience in working with patients with MDR-
TB. 
 
3.6. Sampling Technique 
Purposive sampling was used in the study. Purposive sampling is a type of non-
probability sampling in which the participants are observed and are selected, based on the 
researcher’s interests about which ones will be the most useful and representative (Babbie, 
2010). Purposive sampling can be very useful for situations where you need to reach a 
targeted sample quickly and where sampling for proportionality is not the main concern 
(Babbie, 2010). This type of sampling was used as it permitted the researcher to directly 
target the audiologists who have experience working with MDR-TB. However, like many 
non-probability methods, purposive sampling has the same limitations specifically i.e. the 
ability to generalize from the sample to the population (Johnson & Christensen, 2009). 
 
3.7. Participant Selection 
The following inclusion criteria were used for the selection of participants: 
 Audiologists needed to have had a year or more of working experience, as it allowed 
them to be familiar with the protocols and guidelines used in their practice for 
audiological management of a patient with MDR-TB. 
 Audiologists must have had experience in working with patients diagnosed with MDR-
TB, as the research questionnaire requires a detailed account of the procedures and/or 
modifications that the audiologists are currently making when conducting ototoxicity 
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monitoring. It is, therefore, imperative that the audiologist have knowledge on this aspect 
as it will affect the results of the study by providing incorrect or limited information. 
 
The following exclusion criterion was used for the selection of participants: 
 Audiologists who did not have any experience in working with patients diagnosed with 
MDR-TB. The research study requires the audiologist to account for specific information 
regarding ototoxicity monitoring and MDR-TB; thus, indicating the need for the 
audiologist to have experience with working with this patient population. 
 
3.8. Sample Size 
Assuming that 50% of audiologists correctly follow current audiological practices, 
within a 7% margin of error at 80% power and probability of 95%, a sample size of 196 was 
required. To achieve this sample size and accommodate for a 10% non-response rate, the 
questionnaire was sent to all audiologists in South Africa (1632).  In order to meet this target, 
it was assumed that 25% of the audiologists have had the experience of working with patients 
diagnosed with MDR-TB; thus, the questionnaire was sent to all audiologists and speech 
therapists and audiologists (T. Chetty, personal communication, December 4, 2013).  
 
While 215 responded to the invitation to participate, only 205 completed the 
questionnaire. After applying the participant selection criteria, the study comprised of 93 
participants. The reasons for the low response rates may include:  
a) some participants, while having a dual qualification on the HPCSA register, only practice 
speech therapy,  
b) some therapists who are registered with HPCSA may be practicing abroad and would not 
receive the invitation to participate, and  
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c) some audiologists may not have updated their contact details on the HPCSA database. 
Therefore, the exact number of audiologists practicing in South Africa could not be 
determined, and consequently the sample size calculation may have been affected.  
 
3.9. Description of study participants 
3.9.1. Age and Gender 
Participants were aged between 22 to 41 years, with the mean age being 28 years. 
There were 10 males (11%) and 83 females (89%) who participated in the study. 
 
3.9.2. Language Preference  
Participants were given the option to complete the questionnaire in either English or 
Afrikaans. Eighty- eight participants (95%) completed the English questionnaire, whilst five 
participants (5%) completed the Afrikaans questionnaire. 
  
3.9.3. Work Experience  















































As indicated in figure 3.1., on the previous page, 37 participants (40%) had between 1 
to 3 years of audiology working experience, while 27 participants (29%) had between 3 to 5 
years, 19 participants (20%) had between 5 to 10 years and 10 participants (11%) had greater 
than 10 years of experience.  
 
3.9.4. Types of Institution and Region of Work  









Figure 3.2. Types of institutions participants are currently employed at 
 
As reflected in figure 3.2., above, five participants (5%) work at a community health 
clinic,  21 participants (23%) work at a district hospital, 12 participants (13%) work at a 
regional hospital and 45 participants (48%) work at a provincial hospital. In addition, three 
participants (3%) work at private hospitals and seven participants (8%) work in private 













































Figure 3.3. Number of participants working in each province 
 
Fifty-six participants (60%) were employed in Kwa-Zulu Natal, 12 participants (13%) 
were employed in Gauteng, and eight participants (9%) were employed in Western Cape. In 
addition, nine participants (10%) were employed in the Northern Cape, one participant (1%) 
in Limpopo, four participants (4%) in Mpumalanga and three participants (3%) in Eastern 
Cape. No responses were collected from the North West and Free State province.  
 
3.10. Data Collection  
3.10.1. Data Collection Method 
A survey method was used, as it involved acquiring information about the audiological 
practices employed by South African audiologists regarding ototoxicity monitoring for 
patients with MDR-TB. The questionnaires were accessed via survey monkey. This was a 
quick and effective means of reaching out to the study population. Electronic surveys have 
been developed as it provided the researcher with an easier way of collecting data; however, 
there are numerous reservations regarding issues such as the participants’ willingness to fill 
out an electronic survey (Boyer, Olson, & Jackson, 2001).  Even though there are 
uncertainties surrounding electronic survey, this method of distributing questionnaires is 

















The advantages of using an electronic survey are as follows;  
 Greater ability to present or record information, 
 Electronic surveys provide the participants with a modern and interactive way of 
completing a survey (Boyer et al., 2001). 
 
The disadvantages of an electronic survey are as follows; 
 The lack of response as some participants may not be comfortable with completing a 
survey electronically,  
 The traditional method of completing a survey allows the participant to browse through 
the survey quicker than an electronic survey, 
 The response rate may be poor if the survey is detected as a computer virus or becomes 
spam in the participant’s email (Boyer et al., 2001). 
 
3.10.2. Data Collection Instrument 
A questionnaire developed by the researcher, in consultation with the ASHA (1994) 
and AAA (2009) guidelines for ototoxicity monitoring, was used for the purpose of data 
collection (see Appendix A1 & A2). This was used to understand and/or acknowledge the 
audiological practices utilised by South African audiologists as compared to that of 
international audiologists. It helped the researcher identify the areas of ototoxicity monitoring 
that are being adhered to or modified by audiologists in South Africa. The questionnaire 
addressed aspects that included background information, baseline monitoring, periodic 
monitoring, post treatment as well as audiological management of the patients with MDR TB. 






Motivation for aspects in the questionnaires 
Sections Motivation 
Section A: Biographical 
Details 
(13 Questions) 
This section was used for administrative and statistical purposes. It 
allowed the researcher to establish whether an audiologist was 
conducting ototoxicity monitoring of patients with MDR-TB, which 
would aid in the inclusion criteria of this research study. This section 
allowed the researcher to gain insight into the types of tests that they 
were able to conduct, the type of equipment that they have access to and 
the number of institutions that conduct ototoxicity monitoring. 
 
Section B: Ototoxicity 
Monitoring - Identification 
and Criteria Used for 
Patients with MDR-TB 
(6 Questions) 
This section enabled the researcher to determine the process of early 
identification used by audiologists in South Africa. It helped the 
researcher identify if a good working relationship among staff was 
needed for effective ototoxicity monitoring and provided insight as to 
whether education and training was conducted among staff members. 
This section also served to inform the researcher whether there was an 
effective referral system used for patients with MDR-TB with regard to 
ototoxicity monitoring. 
 
Section C: Ototoxicity 
Monitoring- Baseline Test 
(12 Questions) 
This section was used to gain information as to whether early 
identification for ototoxic hearing loss was being conducted within the 
appropriate time frame, if audiological tests were being conducted and 
whether pre-treatment aspects are covered. 
 
Section D: Ototoxicity 
Monitoring – Monitoring 
Procedures 
(17 Questions) 
This section informed the researcher about the criteria being used for 
identifying specific changes in hearing. It provided an insight on the 
issues audiologists have with regard to monitoring schedules and the 
tests being used to monitor ototoxicity. 
 




This section helped the researcher determine the post-treatment 
protocols used by audiologists in South Africa and provided an insight 
to the scheduled interval evaluations for monitoring. It also focused on 
the audiological management of patients with hearing impairments, 
once MDR- TB treatment has ceased, with regards to amplification, 
assistive listening devices and aural rehabilitation. 
 
 
3.10.3. Data Collection Procedure 
Upon receiving ethical clearance from the University of KwaZulu-Natal Humanities 
and Social Sciences Research Ethics Committee (see Appendix B), a letter requesting the 
postal addresses of all audiologists was sent to HPCSA (see Appendix C). Once this 
information was received, the pilot study was conducted. The purpose of the pilot study was 
to avoid ambiguity, un-interpretable responses from participants and to assess the feasibility 
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of the proposed study (Leedy & Ormrod, 2005). The information document (see Appendix 
D1 & D2), consent form (see Appendix E1 & E2) and questionnaires were emailed to eight 
audiologists informing them of the study. The questionnaire was used in the pilot study and a 
comments form was used to record comments and suggestions (see Appendix F1 & F2). The 
participants, involved in the pilot study were not included in the main study. Audiologists 
within the Uthungulu District of Kwazulu-Natal who had previous experience working with 
patients with MDR-TB were selected to participate in the pilot study. Participants were 
between the ages of 22-35 years old and from the province of Kwa-Zulu Natal. Table 3.2., 
below, indicates the results of the pilot study. 
 
Table 3.2.  
Comments and Suggestions from Pilot Study 
No. Category/ Questions Results 
1 Approximately how many minutes did it 
take you to complete the research 
questionnaire? 
 
Seven (88%) of the eight participants of the pilot 
study were able to complete the questionnaire 
within 20 minutes. 
2 Did you have any difficulty understanding 
the instructions provided? 
 
All (100%) participants of the pilot study indicated 
that questions were simple and precise; thus, 
allowing for clear understanding. 
3 If yes, please provide me with which 
instruction/s and why? 
 
N/A 
4 Did you have difficulty answering any of 
the questions? 
Seven (88%) of the eight participants indicated 
that there was no difficulty answering the 
questions. 
 
5 If yes, please provide me with which 
questions and why? 
 
One (12%) of the eight participants indicated that 
some questions should be open-ended as it differs 
from other institution such as, Questions 15.1., 16, 
31 and 36. 
6 Please provide any comments or 
suggestions that you may have for the 
research questionnaire. 
Three (38%) of the eight participants suggested 
the following changes be made in order for the 
questionnaire to be cohesive: 
 Question 25: “what” was changed to “which” 
 Question 33: it was suggested that question 33.2 
be presented before question 33.3 
 Question 15.1, Question 16 and Question 31 




Upon amendments of the questionnaire, following the review of the results of the pilot 
study, information documents (see Appendix D1 & D2) were posted to all audiologists on the 
HPCSA (1632) database. Once the audiologists agreed to participate (see Appendix E1& E2), 
they were able to complete the questionnaires. All questionnaires were self-administered. 
Participants were given 14 days to complete the questionnaire. If the questionnaire was not 
completed after 14 days, postal reminders were sent with instructions to complete and submit 
thee questionnaire within another 14 day period. After one month, only 33 participants had 
responded. Thus, due to the response rate being extremely low i.e. 33 of the 1632 
audiologists (2%), the researcher had to make amendments to the recruitment procedure and 
obtain permission from University of KwaZulu-Natal Humanities and Social Sciences 
Research Ethics Committee (see Appendix G). 
 
 The amendment permitted the researcher to use audiology associations such as South 
African Association of Audiologists (SAAA) and South African Speech-Language-Hearing 
Association (SASLHA) to send out a broadcast email pertaining to the study and the web 
address to access the questionnaire. Once the broadcast email had been sent out to all 
audiologists on the SAAA and SASHLA databases, participants were given 14 days to 
complete the questionnaire online. Once the 14 day period had lapsed, reminder emails was 
sent once again and audiologists were given another 14 days to participate. This allowed for 
easier access to participants. Participants who had previously responded were urged not to 
complete the questionnaire again. During this time, 10 participants had contacted the 
researcher indicating the following reason for not participating in the research study: 
1. Two respondents reported that they are currently registered as a speech therapist and 




2. Four respondents indicated that they are currently not conducting ototoxicity monitoring. 
3. Another four respondents indicated that they were from academic institutions. 
A total of 205 participants completed the questionnaire. After applying the selection criteria 
only 93 participants remained. Furthermore, upon analysis of the responses, some participants 
failed to answer some of the questions; thus, participants’ numbers may vary in some of the 
results presented in chapter four. 
 
3.11. Data Analysis 
The data from the questionnaires were captured on an excel spreadsheet and analysed 
using the STATA version 13 software. Descriptive methods of analysis were used to interpret 
the results. Descriptive statistics were used to describe the basic features of the study and also 
provided simple summaries of the sample and its measures (Donnelly & Trochim, 2006). 
Some of the “Yes or No” questions were tabulated or converted into graphs. This allowed for 
percentage counts e.g. for each province conducting MDR-TB monitoring.  
 
Thereafter, inferential statistics was utilised in the analysis of data. This helped with 
understanding the current practices employed by audiologists in the management of a patient 
with MDR-TB (Donnelly & Trochim, 2006). The nominal variable must have only two 
values, such as "male" and "female" or "treated" and "untreated." (McDonald, 2009). The 
chi-square test is used to measure the association between two nominal variables (McDonald, 
2009). The chi-square test was used to measure the association between years of experience, 
provinces and private practice and public institutions versus the use of international 
guidelines. Furthermore, open ended questions were analysed by thematic analysis. Data 
analysis, has taken into account that participant responses to some questions may vary due to 
some participants failing to answer all questions. 
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3.12. Reliability and Validity 
“Reliability is the consistency with which a measuring instrument yields a certain 
result when the entity being measured hasn’t changed” (Leedy & Ormrod, 2005, p. 29). “The 
validity of a measuring instrument is the extent to which the instrument measures what it is 
supposed to measure” (Leedy & Ormrod, 2005, p. 28). The questionnaire was formulated 
using the ASHA (1994) and AAA (2009) protocols for guidance of the different aspects that 
needed to be included. Extensive and thorough appraisals of associated research studies were 
conducted during the formulation of the questionnaire in order to ensure that relevant 
questions were included; thus, allowing for content validity. Content validity indicates how 
well the questionnaire represents the components being measured. Pre-checking was 
conducted by a qualified audiologist to ensure validity of the questionnaire (Leedy & 
Ormrod, 2005).   In addition, the pilot study was conducted to determine if the questions were 
clear and concise; thus, ensuring that questionnaire measured what it intended to; thus 
allowing for construct validity. Construct validity aims to measure if the questionnaire 
measured what it is intended to measure (Brink, Van Der Walt, & Rensburg, 2006). 
 
To further ensure the validity and reliability of the questionnaire, simple easy to 
interpret questions were used in the questionnaire (Leedy & Ormrod, 2005). The 
questionnaire was translated into Afrikaans by a qualified educator of Afrikaans (see 
Appendix H) and back translated by a first language Afrikaans speaking nurse (see Appendix 
I) into English., An advantage of using a questionnaire is that participants are able to remain 
anonymous, which results in authentic information. Participants were able to remain 
anonymous, as each questionnaire was individually coded with a participant number and not 
the participant’s name. Additionally, a questionnaire allowed for a large number of 
participants to be targeted (Leedy & Ormrod, 2005). A disadvantage of this method is that a 
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poor return rate was frequently observed in questionnaires. Additionally, participants may 
misinterpret questions, hindering the results of the study (Leedy & Ormrod, 2005). In order to 
prevent this, a pilot study was conducted prior to data collection.  
 
3.13. Ethical and Legal Considerations 
 This study has taken into account ethical and legal considerations. This involved informed 
consent, rights to privacy, protection from harm, anonymity, and honesty between 
professionals (Leedy & Ormrod, 2005).  
 The researcher had completed an online ethics course by the National Institutes of Health 
(NIH) on Protecting Human Research Participants (see Appendix J). 
 Permission to conduct this research study was obtained from the University of KwaZulu-
Natal Humanities and Social Sciences Research Ethics Committee (see Appendix B). 
The current study adhered to the ethical principles of the Declaration of Helsinki. 
 Due to there being low response rate, the researcher had to make amendments to the 
recruitment procedure and obtained approval from the University of KwaZulu-Natal 
Humanities and Social Sciences Research Ethics Committee (see Appendix G). 
 A letter requesting the postal addresses of all audiologists was sent to HPCSA (see 
Appendix C). HPCSA provided the information and the information document was sent to 
all audiologists, informing them of the study and the web address to access the survey. 
 Information documents (see Appendix D1 & D2) contained information about the nature 
of the study, the requirements to complete the questionnaire, their rights as a participant to 
this study and access to the researcher, research supervisor and research office’s contact 
details if they require further information. Participants received a signed copy of the 
information document. The following measures were taken into account for the purpose of 
the study. The researcher was obligated to discuss and explain the nature of the study to 
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the participants. Participants were informed and permitted to withdraw from the research 
study at any given time. 
 Consent documents (see Appendix E1 & E2) were completed by all participants who were 
involved in the study. Each participant was able to print a signed copy of the consent form, 
should they wish. Anonymity and confidentiality of information was assured by allocating 
a number to each questionnaire; thus, no personal information was revealed. This ensured 
participant’s right to privacy. There were no hidden agendas or misconceptions when 
obtaining information (Berg & Latin, 2004).  
 All questionnaires, information and consent documents were available in English and 
Afrikaans, as these are the common mediums of instruction used in South African 
universities. 
 Research questionnaires are locked in a cabinet and only accessed by the researcher 
involved in this study. 
 
3.14. Summary 
This chapter focused on aspects such as the aim, objectives and the data collection 
procedure of the study. A descriptive survey design was used in the study with quantitative 
methods of analysis. Taking into account all the ethical and legal considerations of research, 
an electronic survey method was used to distribute questionnaires to all audiologists in South 
Africa in order to realise the aims and objectives of this study. Once the participants 
completed the questionnaires, the raw data was captured onto an excel spreadsheet and 
statistical analysis was conducted with the assistance of a qualified statistician.  The next 








The results of the study, described in accordance to the objectives of the study, are 
presented in this chapter. To realize the aims of the study, statistical analysis of results was 
conducted. Data was analysed using the STATA version 13 software. Descriptive and 
inferential statistics were used in the analysis of the data. A p-value of less than 5% was 
considered statistically significant. During completion of the questionnaires, some 
participants chose to answer only those questions that they could answer or thought were 
relevant to them; and therefore, participant numbers may vary in the presentation of the 
results. 
 
4.2. Specific Criteria/Protocol Used For Pre-Treatment and Baseline Measures 
4.2.1. Access to Equipment 
Of the 93 participants who had completed the questionnaire, 91 (98%) of the 
participants indicated that they conduct diagnostic hearing assessments, and 58 (62%) of the 
participants indicated that they have electrophysiological equipment at their institutions. The 
figure 4.1., on the next page, indicates the types of electrophysiological equipment 










Figure 4.1. Types of electrophysiological tests available (n=58) 
 
As indicated in Figure 4.1., above, 32 (55%) of the 58 participants have access to 
OAEs, 51 (88%) have access to ABR and 36 (62%) have access to ASSR. 
 
4.2.2. Specific Criteria Used for Identifying Ototoxicity 
4.2.2.1. Awareness of Current Protocols/Guidelines 
Sixty-eight (73%) of the 93 participants indicated that they currently conduct 
ototoxicity monitoring at their institutions. In addition, there was no significant relationship 
(p=0.08) between the work experience of the audiologists and whether ototoxicity monitoring 
was being conducted. Furthermore, 74 (80%) of the 93 participants were aware of ototoxicity 
monitoring guidelines. In addition, those who were aware of ototoxicity monitoring protocols 
had been asked to choose which monitoring protocols they were aware of. 
 
Figure 4.2., on the next page, reflects the ototoxicity monitoring guidelines that 













































Figure 4.2. Awareness of the protocols/guidelines available (n=74) 
 
Figure 4.2., above, indicates that 50 (68%) of the 74 participants are aware of the two 
recommended international guidelines used for ototoxicity monitoring. Ten (14%) 
participants identified the ASHA guidelines; whilst, four (5%) participants identified the 
AAA guidelines. Nine (12%) participants were aware of all guidelines and one (1%) 
participant was aware of a South African guideline. However, South Africa currently does 
not have specific guidelines on ototoxicity monitoring protocols. 
 
4.2.2.2. Working Relationships and In-service Training among Staff 
All 93 (100%) participants believe that the identification of a patient with MDR-TB at 
risk for ototoxicity depends on a good working relationship between the audiologist, 
physician and nurses, and that in-service training amongst the staff involved in the 
management of a patient with MDR-TB is beneficial. With regards to the aspects to be 
addressed during in-service training with staff, 74 (89%) of the 83 participants who answered 
this question, indicated that it should consist of, “what is ototoxicity, when does ototoxicity 
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MDR-TB, what are the associated auditory and vestibular problems, the need for counselling 
and aural rehabilitation”.  
 









Figure 4.3. Responsibility of in-service training (n=83) 
 
Of the 83 participants who answered this question, 66 (80%) participants indicated 
that the audiologist should conduct the in-service training, while two (2%) participants 
indicated that the doctor should conduct the training, three (4%) participants indicated that it 
should be the nurse’s responsibility, two (2%) participants indicated that it should be both the 
doctor and audiologist, and 10 (12%) participants believed that all members i.e. audiologists, 
doctors and nurses should conduct the training. 
 
4.2.2.3. Automatic Referrals for Ototoxicity Monitoring 
Table 4.1., on the next page indicates the types of medications that may require an 
automatic referral for ototoxicity monitoring. 
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Automatic referral based on the type of medication (n=83) 
 
As reflected in Table 4.1., above, 76 (92%) of the 83 participants who responded to 
this question, believed that dihydrostreptomycin, tobramycin, kanamycin, amikacin, and 
gentamicin are the types of medication that would require an automatic referral for 
ototoxicity monitoring. Furthermore, 77 (93%) of the 83 participants indicated that if referrals 
are made automatically when patients are undergoing ototoxic drug treatment, there will be 
an improvement in the current referral system; however, six (7%) participants disagree. 
 
4.2.3. Pre-treatment Measures 
4.2.3.1. Pre-treatment Counselling 
Seventy-five (93%)  of the 81 participants who responded to this question, reported 
conducting pre-treatment counselling, whilst six (7%) participants do not conduct counselling 
prior to the administration of the MDR-TB treatment. The following reasons were provided 
for pre-treatment counselling not being conducted:  
a) Patients were only referred to the audiology departments after the administration of the 
MDR-TB treatment.  
b) Counselling is conducted by the medical personnel prior to treatment. 
c) The audiologist is not involved in the management of the patient at this stage, as patients 
are only seen for diagnostic audiology once the treatment is completed. Baseline and 
monitoring evaluations are carried out at the TB facility. 
d) Referrals are delayed, as patients are usually seen when they present with a hearing loss. 
Medication Frequency Percentage 
Dihydrostreptomycin, stilpain, asprin and gentamicin 1 1% 
Tobramycin and kanamycin 6 7% 
Dihydrostreptomycin, tobramycin, kanamycin, amikacin, and gentamicin. 76 92% 
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The 75 participants who had indicated that they do conduct pre-treatment counselling 
were then required to select the topics that needed to be addressed. Table 4.2., below, 
indicates the topics that were selected by participants as most appropriate to be covered 
during pre-treatment counselling.  
 
Table 4.2 
Topics covered during pre-treatment counselling (n=75) 
Topics Frequency Percentage 
Tinnitus, loss of balance, pharmacological effects, synergistic effect on 
ototoxicity and noise exposure, occlusion effect, hearing loss and potential 
effect on communication ability 
45 60% 
Tinnitus, loss of balance, synergistic effect on ototoxicity and noise 
exposure, occlusion effect, hearing loss and potential effect on 
communication ability 
10 13% 
Tinnitus, loss of balance, synergistic effect on ototoxicity and noise 
exposure, occlusion effect, hearing loss, potential effect on communication 
ability and effects of daily living. 
20 27% 
 
As reflected in table 4.2., above, 45 (60%)  of the 75 participants who conducted pre-
treatment counselling address topics such as tinnitus, loss of balance, pharmacological 
effects, synergistic effect on ototoxicity and noise exposure, occlusion effect, hearing loss 
and potential effect on communication ability, when conducting pre-treatment counselling. 
 
4.2.4. Baseline Measures 
4.2.4.1. Commencement of Baseline Assessment 
Seventy-two (87%) of the 83 participants who responded to this question, conduct 
baseline assessments prior to the administration of the MDR-TB treatment, whilst 11 (13%) 
participants do not conduct baseline assessment. The participants indicated the following 
reasons for not conducting baseline assessments: 
a) Patient is only referred once a complaint of hearing loss is received. 
b) Shortage of staff 
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c) Lack of Occupational Health and Safety (OHS) infrastructure  
d) One booth 
e) No ventilation 
f) Lack of space 
g) Patient is referred from the TB hospital (out of town), which does not have an in-house 
audiologist; therefore, it is considered impractical to conduct a baseline assessment. 
 
Figure 4.4., below, depicts the timeframe for conducting baseline assessment after 









Figure 4.4. Timeframe for conducting baseline assessment (n=72)  
 
Nine (12%) of 72 participants who responded to this question, conduct the baseline 
assessment within 12 hours of the administration of aminoglycoside treatment, while the 
majority of the participants i.e. 33 (46%) conduct the assessment within 24 hours, five (7%) 
participants within 48 hours, 13 (18%) participants within 72 hours, and 12 (17%) 








































4.2.4.2. Audiological Tests Used During Baseline Assessments 
Table 4.3., below, represents the audiological tests that were used during the baseline 
assessment.  
 
Table 4.3  
Audiological tests used during the baseline assessment (n=81) 
Tests Frequency Percentage 
Otoscopic examination, immittance audiometry, air conduction testing, 
bone conduction testing, high frequency audiometry (HFA), speech 
reception testing (SRT), speech discrimination testing (SDT) and 
otoacoustic emissions (OAE) and auditory brainstem response (ABR) 
65 80% 
Otoscopic examination, immittance audiometry, air conduction testing, 
Eustachian tube function (ETF), speech reception testing (SRT), speech 
discrimination testing (SDT) and otoacoustic emissions (OAE) 
10 12% 
Otoscopic examination, immittance audiometry, air conduction testing, 
high frequency audiometry speech reception testing (SRT), otoacoustic 
emissions (OAE) and auditory brainstem response (ABR) 
6 7% 
 
As reflected in Table 4.3., above, 65 (80%) of the 81 participants who responded,  
chose the best possible option of otoscopic examination, immittance audiometry, air 
conduction testing, bone conduction testing, high frequency audiometry (HFA), speech 
reception testing (SRT), speech discrimination testing (SDT) and otoacoustic emissions 
(OAE) and auditory brainstem response (ABR). 
 
4.2.4.3. High Frequency Audiometry and Re-test Confirmation 
Of the 81 participants, 65 (80%) indicated that they do not conduct HFA, whilst 16 
(20%) participants responded that they conduct HFA when conducting baseline assessment. 
Those participants who did conduct HFA were asked which frequencies above 8 kHz were 











Figure 4.5. Frequencies above 8 kHz that are tested (n=16) 
 
In figure 4.5., above, majority i.e. 15 (94%) of the 16 participants conducted pure-
tone audiometry at 12 kHz. Twelve (75%) of the participants conducted pure-tone 
audiometry at 10 kHz. Furthermore, only 4 (25%) of the 16 participants tested at 20 kHz.  
 
Those participants, who do not conduct HFA, had a general consensus in the reasons 











































Do not have the necessary
equipment for HFA
Only test frequency range from
125Hz to 8kHz




From Figure 4.6., on the previous page, 52 (80%) of the 65 participants indicated that 
they do not have the necessary equipment needed for HFA, seven (11%) participants only test 
frequency range from 125Hz to 8kHz, four (6%) participants indicated that no HFA is being 
conducted, two (3%) participants reported that there is not enough time to conduct HFA. 
 
Participants were asked if they perform a re-test to confirm results. Twenty (25%) of 
the 81 participants who responded, indicated that they do not conduct re-tests, while 61 
(75%) participants perform re-tests to confirm results.  Figure 4.7., below, represents some of 
the reason for not conducting re-tests. 
 
Figure 4.7. Reasons for not performing re-test to confirm results (n=20) 
 
Nine (45%) of the 20 participants reported that there are time constraints and large 
caseloads, five (25%) participants indicated that they would only perform a re-test if the 
patient responses were unreliable, two (10%) participants reported that they do not conduct 
re-test as they test accurately, two (10%) participants reported that they conduct monitoring 
assessments, while one (5%) participant indicated that they only provide screening and one 
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4.3. Ototoxicity Monitoring Procedures and Post Treatment Management 
The results are presented in accordance to objective 2, which was to describe the 
ototoxicity monitoring protocols, post treatment and audiological management guidelines 
used by audiologists in South Africa. 
 
4.3.1. Ototoxicity Monitoring Procedures 
4.3.1.1. Use of Criterion to Define Ototoxic Hearing Loss 
Sixty-eight (84%) of the 81 participants who responded to the question reported that 
they do follow a specific criterion, whilst 13 (16%) participants indicated that they do not. 
Furthermore, of the 13 participants who indicated that they do not use a specific criterion to 
define a hearing loss, seven (55%) participants reported that they were not aware of any 
criterion available; two (15%) participants indicated that there was no criterion available for 
South Africa, while another two (15%) participants indicated that it was not applicable to 
them and two (15%) other participants failed to answer the question. 
 
4.3.1.2. Computation of Changes in Hearing Sensitivity 











Participants were also required to choose the correct statement that indicates changes 
in hearing sensitivity. Sixty-two (79%) of the 78 participants who responded to the question, 
correctly selected the criteria to use to identify an ototoxic hearing loss, eight (10%) 
participants follow A and B only, while four (5%) participants follow the 20dB decrease at 
any one test frequency and another four (5%) participants follow 10dB decrease at any 2 
adjacent test frequencies rule.  
 
Furthermore, 78 (99%) of the 79 participants who had responded to the question 
relating to computation of changes in hearing sensitivity, indicated that they use the baseline 
assessment results. One (1%) participant revealed that s/he does not use the baseline 
measures when computing changes in hearing sensitivity, as the baseline assessment has been 
conducted at a different institution.  
 
When the participants were asked if they would conduct a full audiological 
assessment following a change in the patient’s hearing sensitivity, 56 (72%) of the 78 
participants who responded to the question, agreed that they would conduct a full 
audiological assessment, whilst, twenty-two (28%) of the 78 participants reported that they 
do not conduct a full assessment. Those participants, who had indicated that they do conduct 
a full audiological assessment, were then asked to select the tests they would use in the 




Figure 4.9. Audiological tests conducted (n=56) 
 
Of the 56 participants who indicated that they would conduct a full audiological 
assessment if there were significant changes in hearing sensitivity, 27 (48%) participants 
would conduct otoscopy, 28 (50%) participants would conduct tympanometry, 25 (45%) 
participants would conduct acoustic reflex threshold test, 14 (25%) participants would 
conduct OAEs, 28 (50%) participants would conduct air conduction testing, 27 (48%)  
participants would conduct bone conduction testing, 24 (43%) participants would conduct 
speech reception testing, 21 (38%) participants would conduct speech discrimination testing, 
two (4%) participants would conduct ABR, one (2%) participant would conduct ASSR and 
five (9%) participants would conduct HFA.  
 
The 22 participants who had reported that they do not conduct a full audiological test 













































Figure 4.10. Reasons for not conducting the full audiological test battery (n=22) 
 
Eleven (50%) of the 22 participants reported there were time constraints and large 
caseloads, four (18%) participants indicated that they would continue testing from monitoring 
results, two (9%) participants specified that there was no equipment, two (9%) participants 
reported they would only conduct a full audiological assessment once the dosage of the 
treatment is changed, two (9%) participants conduct only air conduction testing, while one 
(5%) participant provides monitoring if changes in hearing is noticed. 
 
4.3.1.3. Assessment of Non-responsive Patients 
Figure 4.11., on the next page, represents the type of test battery used when 





















Figure 4.11. Audiological tests used to assess non-responsive patients (n=77) 
 
Forty-eight (62%) of the 77 participants who responded to this question suggested 
objective means of testing, two (3%) participants indicated behavioral means of testing, one 
(1%) participant reported that no testing be conducted, whilst 26 (34%) participants indicated 
both behavioural and objective tests be conducted. 
 
4.3.1.4. Periodic Testing of Patients Receiving MDR-TB Treatment 
When asked if periodic testing is conducted after every 2-3 days per week for those 
patients receiving MDR-TB treatment, 70 (91%) of the 77 participants who responded, 
indicated that they do not, whilst seven (9%) participants reported that they do conduct the 
assessment after every 2-3 days per week.  
 
The 70 participants who do not conduct the assessment after every 2-3 days per 
week were then asked to choose whether they conduct periodic assessments, weekly, 
fortnightly or monthly. Figure 4.12., on the next page, depicts the timeframe as to when 















































































Figure 4.12. Timeframe as to when periodic assessment is conducted (n=70) 
 
As indicated in Figure 4.12., above, 52 (74%) of the 70 participants reported that they 
conduct assessments monthly and 18 (26%) participants reported that assessments are 
conducted fortnightly.  
 
4.3.1.5. Procedures followed if there are significant changes in hearing sensitivity 
When asked if they report a significant shift in hearing threshold to the physician, 72 
(94%) of the 77 participants who responded, indicated that they would; however, five (6%) 
participants indicated that they would not.  
 
The 72 participants, who indicated that they would report the findings to the 
physician, were then asked to elaborate on the possible changes that the physician could 
make to the patient treatment regime. Figure 4.13., on the next page, depicts the participants’ 














Figure 4.13. Possible changes that a physician could make to treatment regimen (n=69) 
 
Of the 69 participants who responded to the question, 3 (4%) participants indicated 
that the physician would reduce the schedule timing and dosage of the treatment, four (6%) 
participants suggested that there would be a reduction in the dosage of the treatment and an 
increase in the schedule timing, three (4%) participants reported temporary discontinuation of 
the treatment or a switch to a less ototoxic drug. In addition, 37 (54%) participants indicated 
both A and C, and 22 (32%) participants indicated that all treatment options are used.   
 
When asked if they were informed of changes in the treatment regime, 67 (88%) of 
the 76 participants who responded to the question, reported that they were alerted to changes, 
whilst nine (12%) participants reported that they were not alerted to the changes. However, 
they indicated that the changes are documented in the patient’s TB file. 
 
Participants were then asked if they would conduct a new baseline assessment if the 
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to the question, indicated that they would establish a new baseline, while 27 (36%) 
participants indicated that they would not establish a new baseline.  
 
Figure 4.14., below, depicts some of the reasons for not conducting a new baseline 









Figure 4.14. Reasons for not establishing a new baseline if treatment is changed (n=27) 
 
Nine (33%) of the 27 participants indicated that there is not enough time to establish 
new baseline assessments, six (22%) participants reported that the baseline assessments are 
usually conducted at specialised TB hospitals, six (22%) participants indicated that only one 
baseline assessment is needed, whilst six (22%) participants did not see the need for a new 
baseline assessment. 
 
4.3.2. Post Treatment Management 
4.3.2.1. Follow-up Evaluations and Timeframes 
Participants were asked if they would conduct a full audiological evaluation after the 
cessation of MDR-TB treatment. Fifty-three (72%) of 74 participants who responded 
77 
  
indicated that a full audiological assessment would be conducted after the cessation of the 
treatment, while 21 (28%) participants indicated that they do not conduct a full audiological 
assessment. However, they indicated that they would follow-up on monitoring result, only if 
the need arises. Figure 4.15., below, indicates the timeframe in which follow-up evaluations 








Figure 4.15. Timeframe for follow-up evaluations (n=75) 
 
As indicated in figure 4.15., above, 33 (44%) of the 75 participants conducted 
follow-up at three months, six (8%) participants conducted follow-up at six months, one (1%) 
participant conducted assessment at one year, whilst 35 (47%) participants conducted 
assessments at one month, three months, six months and one year. 
 
4.3.2.2. Aural Rehabilitation and Post treatment Counselling 
When asked if there was a difference in the audiological management of a child 
compared to that of an adult, 71 (95%) of the 75 participants who responded, indicated that 
there is a difference, whilst four participants (5%) disagreed. Participants then had to select 
the best possible management for an adult patient. Table 4.4., on the next page, provides the 





































Audiological management of an adult patient (n=74) 
Topics Frequency Percentage 
Hearing aids, assistive listening devices, counselling both to the patient 
and their family. 
5 7% 
Hearing aids, assistive listening devices, counselling both to the patient 
and their family, and audition. 
2 3% 
Hearing aids, assistive listening devices, counselling both to the patient 
and the family, communication strategies, audition; speech-reading and 
possible support groups available. 
55 74% 
A and B 12 16% 
 
Majority of the participants i.e. 55 (74%) of the 74 participants indicated that 
hearing aids, assistive listening devices, counselling both to the patient and their family, 
communication strategies, audition, speech-reading and possible support groups is the best 
possible management for a patient who has completed MDR-TB treatment.  
 
When participants were asked if they conduct counselling after the cessation of 
MDR-TB treatment, 72 (96%) of the 75 participants who had responded, indicated that they 
do, while 3 (4%) participants do not. The participants indicated the following reasons for not 
conducting post treatment counselling: 
a) "Patients defaulted appointments and only return for disability grants when the hearing 
loss has progressed" 
b) "We see patients on a referral basis ONLY. Some of the questions are therefore not 
applicable. The patients are managed by the professor of pulmonology and are technically 
all supposed to be seen at the TB hospitals regionally. We do not book them for follow-
ups/baselines etc." 




Participants were then required to select the most appropriate topics that would be 
addressed during post treatment counselling. Table 4.5., below, indicates the responses of the 
participants relating to post treatment counselling topics. 
 
Table 4.5 
Topics covered during post treatment counselling (n=72) 
Topic Frequency 
What is ototoxicity and the effect it has on the ear, how to optimize the use of 
amplification, the variety of assistive listening devices available and the use of audition 
and speech reading to cope with communication breakdown. 
9 
Nature and etiology of the hearing loss, the effects that the hearing loss has on daily 
living, how to optimize the use of amplification, the variety of assistive listening devices 
available and the use of audition and speech reading to cope with communication 
breakdown. 
44 
All of the above 19 
 
Forty-four (61%) of the 72 participants who responded to this question, indicated 
that the “nature and etiology of the hearing loss, the effects that the hearing loss has on daily 
living, how to optimize the use of amplification, the variety of assistive listening devices 
available and the use of audition and speech reading to cope with communication 
breakdown”, was the most relevant of topics to address during post treatment counselling. 
 
Figure 4.16., on the next page, depicts the responses regarding who should conduct 
















Figure 4.16. Responsibility for conducting post treatment counselling (n=72) 
 
Of the 72 participants who responded to the question, 39 (54%) responded that it 
should be the audiologist, 25 (35%) participants reported that it should be all healthcare 
professionals, four (6%) participants indicated that it should be the audiologist, nurse and 
doctor, while three (4%) participants suggested that it should be the audiologist and the 
physician, and one (1%) participant reported that it should be the doctor. 
 
When asked if counselling should be conducted in the home language of the patient 
67 (89%) of the 75 participants who responded, indicated that counselling should be 
conducted in the home language of the patient, whilst eight (11%) participants indicated that 
it does not need to be conducted in the home language of the patient.  
 
Participants were further questioned as to whether informational pamphlets or 
brochures were given to patients as part of the counselling process. Sixty-one (81%) of the 75 
participants indicated that they do, while 14 (19%) participants indicated that they do not 












































material was due to there being no specific pamphlets or brochures related to ototoxicity and 
hearing loss. 
 
4.3.2.3. Modifications to International Ototoxicity Monitoring Protocols 
Seventy-two (97%) of the 74 participants who responded, indicated that ototoxicity 
monitoring would be easier for audiologists if there were South African guidelines and/or 
protocols available, while two (3%) participants did not believe so. Participants were then 
required to state if they make modifications to the recommended guidelines. Forty-two of the 
74 participants (57%) reported that they do make modifications to the recommended 
guidelines, while, 32 participants (43%) indicated that they do not make any modifications. 
Participants then had to choose one or more options or state the types of modifications they 








Figure 4.17. Modifications made to the international guidelines (n=42) 
 
Twenty-five (60%) of the 42 participants indicated that they only conduct air 
conduction tests, 22 (52%) participants reported that they do not conduct speech audiometry; 
one (2%) participant indicated that only certain frequencies are tested, one (2%) participant 





































































chosen other indicated that they do not conduct immittance audiometry. Furthermore, 
participants were then asked the reason behind performing modifications to the recommended 
guidelines. Figure 4.18., below, depicts the reasons for the modifications made to 








Figure 4.18. Reasons for modifications to international guidelines (n=74) 
 
Sixty-three (85%) of the 74 participants indicated that it is due to time constraints, 
58 (78%) participants reported that it is due to lack of resources, 55 (74%) participants 
suggested that it is due to lack of guidelines and 54 (73%) participants indicated that it is due 
to departments being understaffed. Four (5%) participants reported that the main reason is 
that ototoxicity monitoring is not practiced as often and that the recommended guidelines are 
not suitable for the South African context. 
 
Questions 11, 12, 12.1, 13, 14, 15, 15.1., 16, 17, 18, 19, 20, 21, 22, 23, 24, 24.1., 25, 
26, 27, 28, 29, 30, 31, 33, 33.2., 33.3.;  were used to determine if participants were following 
international guidelines. Of the 93 participants who completed the questionnaire, only 58 
participants had completed all the questions mentioned above. Thirty-five (60%) of the 58 
participants are currently following international guidelines.  
83 
  
Further analysis of results in the current study have indicated that there is a significant 
(p=0.023) relationship between work experience and the use of international guidelines i.e. 
newly qualified audiologists are following international guidelines. There was also a 
significant relationship (p= 0.005) between the province in which audiologists work and the 
use of international guidelines. Furthermore, there was a significant correlation (p=0.024) 
between the type of institutions at which the audiologists work and the use of international 
guidelines, with participants in the public sector aligning more to international guidelines. 
 
4.4. Summary 
This chapter presented the findings of the study. Salient findings were that 80% of 
audiologists are aware of international guidelines, 93% reportedly provide pre-treatment 
counselling; while, 87% of audiologists conduct baseline assessments prior to the 
administration of MDR-TB treatment. Furthermore, 19% of audiologists conduct HFA and 
indicated that there is a lack of high frequency audiometers due is to financial constraints. 
The following were cited as reasons for the modification to the international guidelines:  lack 
of specialised equipment, time constraints and large caseloads, as well as, understaffed 
departments. In addition, 74% of the audiologists are able to conduct periodic assessments 
monthly, while 72% of audiologists conduct a full audiological assessment after the cessation 
of MDR-TB treatment and 96% of audiologists conduct post treatment counselling. These 









The study aimed to describe the audiological practices employed by audiologists in 
the management of adult patients with multi-drug resistant tuberculosis in South Africa. The 
results presented in the previous chapter will now be discussed in accordance to the 
objectives of the study and with reference to appropriate literature. 
 
5.2. Pre-treatment and Baseline Measures 
Ototoxicity monitoring is an essential aspect in the management of a patient with 
MDR-TB, due to the high incidence rate of this disease in South Africa (Bardien et al., 2009). 
Results from the current study have shown that of the 205 participants, 93 (45%) indicated 
that they conduct audiological monitoring of patients with MDR-TB. According to WHO 
(2013), South Africa is one of the five countries that have the largest incidence of TB cases. 
Therefore, it can be assumed that there will also be a large number of people on 
aminoglycoside treatment. This consequently indicates that there should be ototoxicity 
monitoring programs to monitor the audiological status of these people, due to the ototoxic 
nature of aminoglycosides (Duggal & Sarkar, 2007). However, with only 93 participants 
reporting that they conduct monitoring to patients with MDR-TB, it can be deduced that a 
large number of patients do not receive this audiological service.  
 
In order for audiologists to provide ototoxicity monitoring, they would require a set of 
protocols or guidelines to assist them. The findings of the current study revealed that 80% of 
the participants were cognisant of ototoxicity monitoring protocols. Currently South Africa 
does not have explicit ototoxicity monitoring guidelines for audiologists to use; however, 
85 
 
there are two detailed international protocols, i.e. the audiologic management of individuals 
receiving cochleotoxic drug therapy (ASHA, 1994) and the position statement and clinical 
guidelines: ototoxicity monitoring (AAA, 2009). The findings of the current study revealed 
that majority of the participants (63%) were aware of these protocols. This indicates that 
audiologists in South Africa may follow these international guidelines as it is readily 
available to them; however, it is important to note that 1% of the participants are in the belief 
that there are specific ototoxicity monitoring guidelines available in South Africa. However, 
this participant could be referring to the guideline for planning STA services at all levels of 
healthcare by HPCSA (2014). This suggests that there is a need for the participants to obtain 
guidance and training regarding ototoxicity monitoring, and the need for awareness related to 
MDR-TB and ototoxicity monitoring.  
 
In addition, 20% of the participants reported that they were not aware of any 
ototoxicity monitoring criteria/guidelines; however, this would then indicate that this may be 
one of the contributing factors for not conducting ototoxicity monitoring. This indicates that 
the participants may not have received sufficient training on ototoxicity monitoring, and it 
may even indicate their lack of interest, as there are continuing professional development 
activities related to ototoxicity monitoring. In addition, this information is available on the 
internet. Moreover, the results suggest that audiologists need to be proactive in accessing 
information related to their expertise. Results of the current study revealed that recently 
qualified audiologists are aligning to the international guidelines. The researcher speculates 
that this could be due to the more recent audiology curriculum placing emphasis on 
ototoxicity monitoring, due to the high burden of disease in South Africa. In addition, the 
findings revealed that more audiologists in the public sector align to international guidelines. 
The researcher postulates that this could be due to newly qualified audiologists still being 
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employed in the public sector, while those audiologists in private practice have more 
audiology work experience. Ototoxicity monitoring is within the scope of practice of an 
audiologist, with the planning and implementation of the program being one of their 
responsibilities (Konrad-Martin et al., 2005). 
 
ASHA (1994) indicated that a collaborative effort needs to be made for the 
implementation and continuations of a program to be a success which suggests that there is a 
need for a good working relationship among healthcare professionals. This is emphasised by 
the finding of the current study, as all participants indicated that the identification of the 
patients at risk for hearing loss depends on a good working relationship among all health 
professionals. This, however, would only be possible if health professionals understand what 
ototoxicity is and the importance of audiological services to a patient with MDR-TB, as has 
been demonstrated by Khoza-Shangase (2013). Therefore, it is essential for health 
professionals managing patients with MDR-TB to be in-serviced about ototoxicity in this 
patient population (AAA, 2009), as has been agreed by all the current study participants.  
 
The findings from the study revealed that 89% of the participants indicated that the 
topics that should be incorporated when conducting in-service training with staff should 
include; “what is ototoxicity, when does ototoxicity occur, what happens to the ear and its 
function, what are the ototoxic drugs involved in MDR-TB, what are the associated auditory 
and vestibular problems, the need for counselling and aural rehabilitation”. This is needed as 
all healthcare professionals who are involved in the management of a patient with MDR-TB 
would understand the need for ototoxicity monitoring; hence, assist with early identification 
of patients who are at risk of developing ototoxicity. This indicates that although the 
participants are aware of the importance of in-service training as well as appropriate topics 
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that need to be addressed during in-service training, they may not necessarily be conducting 
in-service training, as a study by Khoza-Shangase (2012) illustrated that 74% of the 
healthcare workers indicated that they lacked awareness in terms of ototoxicity and the 
symptoms that a patient may present with as a consequence of ototoxic treatment.  
 
Furthermore, as reflected in figure 4.3., on page 62, majority (80%) of the participants 
suggested that the audiologist should conduct this in-service training, however, 2% of the 
participants suggested that it should be the doctor, 4% of the participants reported that it 
should be the nurses, 2% of the participants indicated that it should be both the audiologist 
and the doctor, whilst 12% of the participants believe that it should be the responsibility of all 
healthcare professionals. Although, it is important for all healthcare professionals to conduct 
in-service training so as to improve trans-disciplinary skills and knowledge base of ototoxic 
drugs, it is the responsibility of the audiologist to provide awareness related to ototoxicity. 
Thus, suggesting that all in-service training related to ototoxicity monitoring should be 
conducted by the audiologist (AAA, 2009), as the audiologist is the professional most closely 
involved in the assessment of ototoxicity and who should be the most knowledgeable about 
signs and symptoms, as well as, the ototoxic medication. This is re-iterated by the findings of 
the current study, which revealed that 92% of the participants selected the correct group of 
ototoxic medication. This revealed that the participants are aware of the types of ototoxic 
medication used in MDR-TB treatment that would require monitoring, and this information 
should be relayed to the nurses and physicians through in-service training. If there is adequate 
in-service training, it is likely that there would be more referrals of patients who are 
undergoing ototoxic drug treatment. Furthermore, 93% of participants believe that patients 
who undergo ototoxic drug treatment should be automatically referred for audiological 
monitoring and this would result in an improvement to the current referral system. As 
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medical practitioners are responsible for providing comprehensive healthcare services to all 
patients who require medical care, this would then include ototoxicity, as ototoxicity results 
from the use of often life threatening treatment (Khoza-Shangase & Jina, 2013). However, 
7% of the participants disagreed; this could indicate that that these participants are concerned 
that some healthcare professionals may lack the knowledge of the symptoms or signs 
associated with ototoxic drugs which may then lead to inappropriate/unnecessary referrals to 
audiology departments (de Andrade et al., 2009); highlighting, again the importance of in-
service training. If healthcare professionals are knowledgeable about ototoxicity in the MDR-
TB patient population, patients will be referred to the audiology department prior to 
commencement of treatment, as this will allow the audiologist to conduct pre-treatment 
counselling. 
 
Pre-treatment counselling is an essential aspect of ototoxicity monitoring as it allows 
the audiologist to establish rapport with the patient. It allows the patient and their family to 
feel actively involved in the treatment process. Results of the current study revealed that 93% 
of the participants conduct pre-treatment counselling. The reason cited for the lack of pre-
treatment counselling, was that patients were only referred to the audiology department after 
the commencement of the MDR-TB treatment. This indicates that due to there being a break 
between services in ototoxicity monitoring, the participants may have to conduct counselling 
during the follow-up evaluations, or it is likely that the pre-treatment counselling may not be 
conducted or may be conducted by medical staff. However, pre-treatment counselling related 
to aspects of ototoxicity needs to be conducted by the audiologists, as audiologists are 
obligated to provide information regarding the adverse effect of ototoxic treatment on their 
auditory and vestibular system (AAA, 2009).  
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According to ASHA (1994), pre-treatment counselling should include the clinical 
notes of the physician involved in the management of a patient with MDR-TB, regarding the 
risks and benefits of the ototoxic treatment and the audiologists should counsel on aspects 
such as the signs and symptoms of cochlear damage and the possible communication 
difficulties that the patient may incur. The finding of the current study revealed that 60% of 
the participants chose the similar topics as suggested by ASHA (1994). This indicates that 
while majority of the participants (93%) are conducting pre-treatment counselling, a large 
percentage of them do not address all of the relevant aspects. Pre-treatment counselling is the 
time in which you are able to prepare the patient and their family for the possible changes to 
the livelihood of the patient that may occur due to changes in hearing sensitivity. It also 
provides an opportunity for the audiologist to explain to the patient with MDR-TB, the need 
to conduct a baseline assessment. 
 
The need for a baseline assessment is to document the hearing status of the patient 
prior to the administration of the MDR-TB treatment (ASHA, 1994). Results of the current 
study revealed that 87% of the participants conduct baseline assessment prior to the 
commencement of MDR-TB treatment. This indicates that majority of the participants who 
conduct ototoxicity monitoring are following the international protocols, as audiologists need 
to establish the current hearing status prior to any effects experienced during treatment 
(Konrad-Martin et al., 2005). The reasons cited for not conducting baseline assessment 
include delays in referrals, lack of resources and/or staff and patients are assessed at 
specialised TB institutions. This indicates that audiologists are facing challenges that prevent 
them from conducting baseline assessments. These challenges include, baseline assessments 
being conducted at different institutions and handover or access to the results is not available 
to them or the patient is only referred for an audiometric evaluations if a hearing impairment 
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is noted by the physician. Furthermore, those patients who have baseline assessment 
conducted at specialised TB institutions need to have well documented audiograms and 
summary of results in their TB files if they are then going to be referred to another institution. 
According to the AAA (2009) and ASHA (1994) guidelines, baseline assessments should be 
conducted within 72 hours after the administration of the ototoxic treatments. As depicted in 
figure 4.4., on page 65, only 17% of the participants are not compliant in this regard. This 
indicates that these patients were not being correctly monitored and this could affect the 
outcomes of the results. This would further suggest that timely assessment requires a highly 
efficient patient identification and/or referral system (AAA, 2009), which again emphasises 
the importance of in-service training and a trans-disciplinary approach to patient 
management.  
 
According to AAA (2009), the following tests are recommended during baseline 
assessments, “pure tone thresholds in the conventional frequency range, HFA, tympanometry, 
speech audiometry, and testing of OAEs” (p. 5). As reflected in Table 4.3., on page 66, 80% 
of the participants are knowledgeable of the audiological tests that are to be used during 
baseline measures. This indicates that majority of the participants are aware of the types of 
tests that are necessary when conducting ototoxicity monitoring. Furthermore, this indicates 
that there has been improvements in testing patients who present with ototoxicity, as until 
very recently, only conventional testing methods, i.e. the puretone audiometric testing was 
used; however, recently, more specific information is gained by use of HFA and OAEs which 
would allow for early detection of an ototoxic hearing loss (Venter, 2011). Thus, making 
baseline audiometry a crucial aspect for the successful implementation of an ototoxicity 




However, majority of the participants (80%) do not conduct HFA as there is a lack of 
high frequency equipment in audiology departments. This indicates the constraints 
experienced by audiology departments relating to HFA and its use in South Africa. HFA 
enables the audiologists to gain threshold information from 8 kHz to 20 kHz, which is the 
frequency region to be initially affected by the use of aminoglycosides, as demonstrated by 
Appana (2013). This indicates that it is imperative that HFA be included in the assessment as 
it includes the upper regions of hearing which is not usually tested during conventional 
audiometric evaluation (Venter, 2011). However, there is a lack of the necessary specialised 
equipment required to conduct HFA due to financial constraints (Koekemoer & Ndjeka, 
2013). This was substantiated by the findings of the current study, as depicted in Figure 4.6., 
on page 67, which cited the lack of high frequency audiometers as one of the main reason for 
not conducting HFA. In addition, service delivery is greatly affected, as specific results 
related to higher frequencies are able to provide early identification of an ototoxic hearing 
loss which would reduce the number of patients who are referred to audiology department 
once irreversible damage to their auditory system has occurred (Konrad-Martin et al., 2005).  
 
Furthermore, the findings of the current study, as reflected in Figure 4.5., on page 67, 
revealed that 94% of the participants tested at 12 kHz and 25% of the participants tested at 20 
kHz. This indicates that some audiologists may have standard audiometers, with an extended 
frequency range of up to 12 kHz, which would allow many audiologists to test in that 
frequency range. Furthermore, this may indicate that the participants are using the 𝑡ℎ61 -octave 
test protocol, which provides earlier detection of ototoxicity (Fausti et al., 1994). Compared 
to testing in 𝑡ℎ61 -octave steps above and below 8 kHz, testing conventional frequencies alone 
resulted in initial ototoxic hearing change being missed or detected later (Fausti et al., 2003). 
This would then delay the management of a patient with MDR-TB, which needs to be 
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identified early as these patients, due to fatigue and illness, may not be consistent during 
conventional test frequencies and may require re-test of frequencies. 
 
Re-tests are essential to confirm results of patients that may respond inconsistently 
during behavioural testing (ASHA, 1994). The findings of the current study revealed that 
75% of the participants conduct re-tests. As depicted in Figure 4.7., on page 68, reasons cited 
for not conducting re-tests include financial constraints, time constraints and large caseloads, 
participants reporting that they test accurately, participants reporting that they conduct only 
monitoring assessments, or only conducting screening. Furthermore, five (25%) participants 
reported that they only conduct re-tests when patient responses are unreliable. According to 
Naidoo (2006), service delivery of audiological services are hindered by factors related to 
budget cuts, lack of staff and lack of awareness of the need for audiological services. This 
would then indicate that the constraints experienced in audiology departments would lead to 
higher caseloads, lack of upgrading the department and lack of employment for audiologists, 
which further, indicates that the implementation of a successful ototoxicity monitoring 
program would be disrupted. 
 
5.3. Ototoxicity Monitoring Procedures and Post Treatment Management 
The use of a criterion, available in the international guidelines, enable audiologists to 
clearly define an ototoxic hearing loss and provides a way of assisting the audiologist in 
making informed decisions about the management of a patient with MDR-TB. Results of the 
current study revealed that 84% of the participants are following a criterion when defining an 
ototoxic hearing loss. The need for a criterion decreases the occasional false-positive 
identification which delays detection of the ototoxic process (Konrad-Martin et al., 2005). Of 
concern is the 16% of participants who do not use a criterion, due to them not being aware of 
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a criterion and none being available for South Africa. This, therefore, indicates that some 
participants need to become aware of the resources they have available, albeit international. If 
a criterion is not being used, a question arises – “How is ototoxic hearing loss being 
calculated?” 
 
According to ASHA (1994), the following indicates ototoxic hearing loss: (a) 20 dB 
decrease at any one test frequency, (b) 10 dB decrease at any two adjacent test frequencies, or 
(c) loss of response at three consecutive test frequencies where responses were previously 
obtained. The findings in the current study, as reflected in Figure 4.8., on page 69, revealed 
that 79% of the participants, who responded to the question, correctly selected the criterion to 
utilise to identify an ototoxic hearing loss. The use of a criterion is essential as it would allow 
audiologists to make clinically appropriate decisions based on the progression of the hearing 
loss, as well as, assist in conveying information to the physician on the severity of ototoxicity 
that the patient may exhibit.  
 
The computation of the changes in hearing sensitivity provides a method of noticing if 
changes to the treatment regimen need to be made. The methods suggested in the 
recommended guidelines, i.e. comparing the baseline assessment to that of the follow-up 
evaluation, allows the audiologist to use a standard method of determining the effect of the 
ototoxic drugs on the auditory system. The findings of the current study revealed that 99% of 
the participants use the baseline assessment when computing changes in hearing sensitivity. 
Computation of the changes in hearing sensitivity during each follow-up assessment is 
calculated in conjunction with the baseline assessment results (ASHA, 1994). This is done, so 
as to document the changes from before the commencement of treatment till the cessation of 
the ototoxic treatment. This indicates that the participants are following the recommended 
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international guidelines and it is important as, this would define if there are changes to 
hearing sensitivity and determine if the audiologists needs to inform the physician of the 
changes and make relevant changes to treatment regimen (Konrad-Martin et al., 2005). Once 
there is change to the patients hearing status, a full audiological evaluation is required, as 
changes in hearing sensitivity may be a result of middle ear pathologies (ASHA, 1994).  
 
Therefore, participants were asked if they would conduct a full audiological 
assessment if there was a change in the patient’s hearing sensitivity. Seventy-two percent of 
the 78 participants who responded indicated that they would conduct a full audiological 
assessment. Those who do not conduct a full audiological assessment cited the following 
reasons: insufficient time and large caseloads. In addition, the participants indicated that they 
would continue from the baseline assessment results, as shown in Figure 4.10., on page 72. 
According to Venter (2011), audiologists often indicate that time constraints, cost 
effectiveness and efficiency are the common challenges that are faced when implementing a 
successful ototoxicity monitoring protocol. These have been reported on the basis that it is a 
hindrance to audiological services that would need to be implemented; however, little is done 
to overcome these constraints by higher management in New Zealand (Venter, 2011). 
 
In addition, the findings of the current study, as illustrated in Figure 4.9., on page 71, 
revealed that majority of the participants utilise the basic audiological test battery as the full 
audiological test battery for monitoring ototoxicity, with 25% and less of the participants 
using electrophysiological tests. This indicates that many audiology departments in South 
Africa do not possess specialised equipment such as, ABR, ASSR and HFA. This poses a 
challenge to service delivery (Naidoo, 2006), especially when assessing non-responsive 
patients. This is further reflected in the study by Seddon et al. (2012), who indicated that 
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specialised audiological equipment is available at specialised institutions. From anecdotal 
experience, audiologists generally refer these patients to these specialised institutions which, 
results in a delay in monitoring ototoxicity due to the institutions having waiting lists for 
specialised electrophysiological testing, especially needed for a non-responsive patient. 
 
The assessment of a patient with limited responses or no response requires some 
modification that needs to be made to the test battery used. According to ASHA (1994), both 
behavioural and objective means of testing need to be utilised. However, only objective tests 
may be used to assess a non-responsive patient. The current study, as reflected in Figure 
4.11., on page 73, indicates the 34% of the participants reported that they would use objective 
and behavioural tests and 62% of the participants indicated that an objective test be used 
when assessment a non-responsive patient. While the participants acknowledge the objective 
tests need to be used when assessing non-responsive patients, one’s attention is drawn back to 
the lack of these specialised equipment at the different institutions. This indicates that non-
responsive patients may not necessarily be receiving appropriate audiological services and 
intervention.   
 
According to the international guidelines, patients who are undergoing ototoxic 
treatment need to be monitored 2-3 days per week (ASHA, 1994). In this way any changes to 
the auditory system would be detected early and thus the treatment regimes would be 
amended to suit the needs of the patient. However, a resounding 91% of the participants 
reported that they do not conduct assessment 2-3 days per week. This is understandable as 
audiology departments have a number of challenges; one being the caseload and time 
constraints they experience that would not allow these assessment to occur so often. This is 
further supporter by Venter (2011), which indicated that only 31% of the patient being 
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monitored for ototoxicity would have follow-up assessments. Thus, as depicted in Figure 
4.12., on page 74, 56% of the participants reported that they conduct assessments monthly 
and 26% of the participants reported that it is conducted fortnightly. From the anecdotal 
experience of the researcher, patients usually take their MDR-TB treatment either 3-5 times a 
week; however, patients are usually booked monthly for their follow-up evaluation. This 
indicates that South African audiologists are modifying the recommended guidelines in a way 
that does not reflect negatively on the audiological services provided but rather in a way of 
relating to the South African context. 
 
One of the main reasons for ototoxicity monitoring is to alert the physician if there 
have been significant changes to hearing sensitivity. In this way, the audiologist is viewed as 
an integral component in the team when it comes to the management of a patient with MDR-
TB. The study revealed that 94% of the participants indicated that they would alert the 
physician if there are changes to the hearing status. In this way, the audiologist is able to 
convey information to the physician on the progression of ototoxicity so that the physician 
would be able to make appropriate changes to the treatment regime, such as reduction in the 
dosage, the scheduled timing of the dosage, temporary discontinuation or a switch to a less 
ototoxic drug (Mattucci & Vasquez, 2003). 
 
Audiologists need to be cognisant of the treatment options the physician has when 
changes in hearing sensitivity are noted. This is reflected by approximately 54% of the 
participants, as reflected in Figure 4.13., on page 75, who selected the correct option.  
 
In turn, audiologists need to be aware of any changes that the physician may make to 
the treatment regime; however, the results of the study revealed that 88% of the participants 
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were alerted to any changes made by the physician. This indicates that audiologists are an 
essential component in the management of a patient with MDR-TB and physicians are 
documenting detailed results in the patient TB file, as well as, indicating that audiological 
monitoring is required in order to track ototoxicity. It is important for an audiologist to be 
alerted as this may affect the ototoxicity monitoring program they may have in place for the 
patient (Mattucci & Vasquez, 2003). For instance, if the physician has decided to change the 
type of drug of the patient undergoing MDR-TB treatment, the audiologist needs to conduct a 
new baseline assessment (ASHA, 1994). According to the results obtained in the study, only 
64% of the participants indicated that they would establish a new baseline measure. However, 
36% of the participants reported that they would not conduct a new baseline measure as they 
could simply use the initial baseline and that they did not see the appropriateness of 
conducting another baseline assessment as they have one already. This indicates that these 
audiologists do not fully understand the need for conducting a new baseline measure or may 
not be aware of the purpose related to its establishment. Thus, accurate monitoring of the 
patient hearing status would not be documented and changes to hearing sensitivity in follow-
up evaluations would go unnoticed which may lead to the failure of an ototoxicity monitoring 
program. 
 
The follow-up evaluations are required so as to monitor if the changes to the hearing 
sensitivity have stabilised following the cessation of treatment (ASHA, 1994). Thus, there is 
a need for a full audiological evaluation to be conducted after the cessation of MDR-TB 
treatment. According to the study, 72% of the 74 participants, who responded, indicated that 
they would conduct a full audiological assessment; this indicates that these audiologists are 
following the international guidelines. Follow-up evaluations are usually conducted at 3 
months, 6 months and one year after treatment has ceased (ASHA, 1994). The finding from 
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the current study, as shown in Figure 4.15., on page 77, revealed that 47% of the 75 
participants who responded to this question conduct the assessment at those recommended 
timeframes. This further indicates that the participants are following international guidelines, 
as HPCSA indicated that rehabilitation after the cessation of treatment extends from 6 weeks 
to 6 months (HPCSA, 2014); however, this is a fairly new guideline that some audiologists 
may not be aware of.  
 
Aural rehabilitation forms an essential part in the management of a patient with 
MDR-TB. Adult aural rehabilitation programs differ from children programs as adults may 
present with hearing impairment later on in life and have already developed speech and 
language skills (Alpiner & McCarthy, 2000). According to the study, 95% of the 75 
participants, who responded to this question, indicated that there is a notable difference 
between the aural rehabilitation programs of a child compared to that of an adult.  
 
According to Alpiner and McCarthy (2000), these general steps need to be included in 
an adult rehabilitation program: 
a) The assessment of hearing and the impact of hearing loss. 
b) Hearing aid evaluation, its use and/or need for assistive listening devices 
c) Audition and speechreading 
d) Development of an individualised aural rehabilitation program which includes both the 
patient and family members. 
This was evident in the study, as reflected in Table 4.4., on page 78, as 74% of the 74 
participants who responded to this question, indicated that “hearing aids, assistive listening 
devices, counselling both the patient and the family, communication strategies, audition; 
speech-reading and possible support groups available” should be covered during aural 
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rehabilitation. This would then indicate that those patients with MDR-TB would be receiving 
sufficient audiological management following the identification of a change to their hearing 
status that would allow them to accept and adapt to these changes more easily than those who 
do not have support. Furthermore, supporting a patient through counselling remains to be an 
essential aspect of an aural rehabilitation program; thus, indicating the need for audiologists 
to develop and implement an aural rehabilitation program that is specific for the needs of a 
patient with MDR-TB (Pienaar et al., 2010). 
 
Post treatment counselling is an essential aspect in the management of a patient with 
MDR-TB, as this will allow the patient to cope with the changes in hearing sensitivity caused 
by the MDR-TB treatment (Alpiner & McCarthy, 2000). The study revealed that 96% of the 
75 participants, who responded to this question, indicated they would conduct post treatment 
counselling; however, the 4% of participants reported that they would not conduct post 
treatment counselling due to patient defaulting on appointments or only attending the clinic 
when hearing aids are to be fitted. Those who do conduct post treatment counselling 
indicated that the nature and etiology of the hearing loss, the effects that the hearing loss has 
on daily living, how to optimize the use of amplification, the variety of assistive listening 
devices available and the use of audition and speech reading to cope with communication 
breakdown, were the most relevant topics to be addressed during post treatment counselling. 
This would assist the patient by improving their skills and help the patient optimise the use of 
their amplification (Alpiner & McCarthy, 2000). The audiologist needs to understand the 
needs of the patient and assist them appropriately. 
  
Post treatment counselling is important; however, counselling should be conducted by 
all professionals involved in the management of a patient with MDR-TB (AAA, 2009). Each 
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healthcare professional should counsel the patient on aspects related to their treatment. Thus, 
the current study, as depicted in Figure 4.16., on page 80, revealed that 54% of the 
participants indicated that counselling related to ototoxicity should be conducted by 
audiologists. Although, audiologists have the expertise to provide counselling related to 
ototoxicity, especially once cessation of MDR-TB treatment, no mention of post treatment 
counselling is evident in the HPCSA guidelines. However, the international guidelines 
emphasised that audiologists play a key role in the facilitation of post treatment counselling 
so as assist the patient with communication problems they may exhibit due to the MDR-TB 
treatment (ASHA, 1994). 
 
In South Africa, there are many languages, which may pose as a challenge to 
audiologists by creating language barriers and make the management of a patient with MDR-
TB more difficult. It is by right of the patient to have services rendered to them in their home 
language (van Dyk, 2008). Thus, the findings of the study revealed that 89% of the 
participants indicated that they would conduct counselling in the home language of the 
patient. Furthermore, a patient is entitled to information relating to their treatment they are 
receiving (DOH, 2001). This would include both verbal and written form of information 
(DOH, 2001). Thus, the study revealed that 81% of the participants provide pamphlets or 
brochures to their patients. However, accurately translated informational pamphlets or 
brochures are needed in order to provide correct information (van Dyk, 2008). Moreover, the 
use of pamphlets, brochures or informational guides may also prove to be challenging, if they 




5.4. Modifications to Recommended Ototoxicity Monitoring Protocols 
Context-relevant standards allow for easier implementation as it will support the need 
of the professionals and the patients involved in the process of MDR-TB management. 
According to the study, 97% of the 74 participants, who responded, indicated that ototoxicity 
monitoring would be easier for audiologists if there were South African guidelines and/or 
protocols available. This indicates that the participants have noted that international 
guidelines may not be suitable for the South African context and thereby would attempt to 
make modifications to these guidelines to make them contextually relevant. Thus, 57% of the 
74 participants indicated that they do make modifications to the international guidelines. The 
modifications, as illustrated in Figure 4.17., on page 81, include not conducting speech 
audiometry, only testing certain frequencies and not conducting immitance audiometry. This 
has an impact on the program as a standard protocol is not being followed and would then 
impact on the results obtained from the patient. The information obtained from the patient 
indicates the progress or stabilisation of ototoxicity. The use of standardised methods of 
testing make it easier to document the progression of ototoxicity; thus, allowing for a more 
efficient referral system to specialised services and to gain the epidemiological statistics 
needed to improve or gain further insight into ototoxicity (Mattucci & Vasquez, 2003). 
Furthermore, standardised methods of testing would improve clinical case management 
within a TB program, as it would provide the schedule timing of administration of treatments 
or the possible changes that occur if there is progression in ototoxicity (Seddon et al., 2012).  
 
The findings of the study also revealed that 60% of participants are currently 
following international guidelines. This indicates that most participants are using and 
possibly modifying the current international guidelines in order to provide the services to 




5.5. Summary  
This study aimed to describe the audiological practices employed by audiologists in 
the management of an adult patient with MDR-TB in South Africa. Pre-treatment 
counselling, baseline practices, follow-up evaluations and post treatment sum up the basis of 
an ototoxicity monitoring program. Majority of the participants (92%) have been able to 
identify those patients who would require ototoxicity monitoring and 93% provide pre-
treatment counselling.  
 
With regard to baseline practices, 80% of participants follow the international 
guidelines even though many constraints are experienced within audiology departments. 
Although, a large percentage of participants are able to conduct the baseline assessment, it is 
clear that follow-up evaluations may not be conducted as frequently. Furthermore, HFA is 
lacking in South Africa, as 80% of the participants are unable to conduct this test due to the 
lack of equipment. The findings of the current study revealed that 91% of the participants 
were not able to meet the requirements of the international guidelines of conducting 
monitoring evaluations after every 2-3 day per week. Once again, indicating that due to the 
constraints experienced in audiology departments ototoxicity monitoring may be hindered or 
implemented with modifications that are suitable to the South African context. 
 
This chapter discussed the results of the study in relation to literature. From the above 
discussion, it is apparent that the aims of this study were realised. Nevertheless, there were 
limitations of this study which will be discussed in the following chapter. Reference to future 





CONCLUSION, LIMITATIONS AND RECOMMENDATIONS  
 
6.1. Introduction 
This chapter provides a summary of the main findings of the study, highlights the 
limitations of the research conducted, as well as, the recommendations for future research.  
 
6.2. Summary of Main Findings 
 While South Africa currently does not have specific guidelines for ototoxicity 
monitoring, there are audiologists who are practicing in a way that allows for maximising of 
resources in an effective manner to ensure a high quality of healthcare. Therefore, this study 
aimed to describe the audiological practices employed by audiologist in the management of a 
patient with MDR-TB, as the findings may be used to inform policy for a contextually 
relevant evidence-based ototoxicity monitoring program for patients with MDR-TB. The 
findings of this study revealed that audiologists do not conform to all aspects of the AAA 
(2009) and ASHA (1994) ototoxicity monitoring protocols and are, thus, making 
modifications. A summary of the finding is listed below: 
 For an audiologist to have a foundation of where to begin to develop and implement an 
ototoxicity monitoring protocol, they would require guidelines. In this regard, 74 (80%) 
of the 93 participants are aware of the international ototoxicity monitoring guidelines. 
This indicates that some audiologists are currently following the international guidelines 
that are available to them; however, it also suggests that due to the audiologist utilising 




 Seventy-six (92%) of the 83 participants were able to identify the types of treatment that 
are ototoxic. 
 Seventy-five (93%) of the 81 participants conduct pre-treatment counselling. However, 
the researcher cannot assume that the patient receives sufficient information related to the 
treatment of MDR-TB and the associated symptoms. Pre-treatment counselling aids in 
adherence to medical treatment, as well as, attendance to follow-up evaluations and 
acceptance to changes in the auditory system that may occur. 
 The use of HFA is an essential test used in ototoxicity monitoring; however, 65 (80%) of 
81 participants reported that they do not conduct HFA, due to the constraints within the 
audiology department, such as lack of equipment, time constraints and the lack of 
context-relevant ototoxicity monitoring programs. 
 Results of the current study revealed that 70 (91%) of the 77 participants do not conduct 
follow-up evaluations after every 2-3 days per week. This may be due to time constraints, 
increased workload, lack of trained staff and resources. However, majority of the 
participants i.e. 52 of the 70 participants (74%) conduct follow-up evaluations monthly.  
 The type of modification that is commonly made to the recommended ototoxicity 
monitoring protocol is that the participants only conduct air conduction testing or do not 
conduct speech audiometry. The reasons for the modification of the international 
guidelines are time constraints, high caseloads and lack of resources.  
 
6.3. Limitations of the study 
The study set out to describe the audiological practices employed by audiologists in 
the management of a patient with MDR-TB in South Africa. The findings of this study need 
to be considered in relation to identified limitations of the research: 
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 The low response rate to the research study, with 93 participants being included in the 
study. Some participants, while having a dual qualification on the HPCSA register, only 
practice speech therapy and some therapists that are still registered with HPCSA may be 
practicing abroad. Therefore, the exact number of audiologists practicing in South Africa 
could not be determined. 
 Participants’ numbers vary in reporting of results as some participants failed to respond to 
some of the questions. This has been identified as possibly affecting the reliability and 
validity of the findings. 
 Majority of the participants were also from Kwazulu-Natal, and therefore results cannot 
be generalised to the broader audiology community of South Africa.  
 More information such as the impact of the modification to international guidelines 
related to the South African context and its benefits should have been addressed, as this 
would have provided insight into its application to the South African context. 
  
6.4. Recommendations for Future Research 
6.4.1. Research Implications 
 A qualitative research method using telephonic interviews, such as that conducted by 
Venter (2011) would allow audiologists at specialised TB hospitals to elaborate on the 
need for ototoxicity monitoring, the modifications and its benefits to the patient. 
 Conduct audiological testing with the modifications that have been mentioned in this 





6.4.2. Clinical Implications  
 Pre and post treatment counselling is considered to aid or assist the patients in adherence 
to MDR-TB treatment. Therefore, all audiologists should ensure that patients with MDR-
TB are counselled. This should be looked into and address in a multi-disciplinary team. 
 Audiologists should utilise HFA and SRO in the South African context, as these have 
proven to be effective means of ototoxicity monitoring. 
 Audiologists should work together to develop a contextually relevant pamphlet on 
ototoxicity, which should be available in the 11 official languages. 
 
6.5. Summary 
This final chapter has presented the main findings of the research study, limitations of 
the research and recommendation for future studies. South Africa is one of the countries that 
has the highest MDR-TB infection rates which has put strain on the healthcare system. This 
highlights the use of more aminoglycosides and thus put these patients at risk for developing 
an ototoxic hearing loss. This, therefore, indicates the need for ototoxicity monitoring in 
South Africa, so that patients may benefit from the services provided, by being involved in 
the process of making an informed decisions. However, there are currently no specific 
guidelines for ototoxicity monitoring in South Africa. However, there are audiologists who 
are practicing in a way that allows for maximising of resources in an effective manner to 
ensure a high quality of healthcare. Therefore, this study aimed to describe these practices so 
that the information can be used to devise contextually relevant evidence-based ototoxicity 
monitoring protocols for patients with MDR-TB. Furthermore, the findings of this study may 
help motivate for a more in-depth Department of Health (DOH) and HPCSA ototoxicity 
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